paclitaxel has been researched along with Peripheral Arterial Diseases in 360 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 161 (44.72) | 24.3611 |
2020's | 199 (55.28) | 2.80 |
Authors | Studies |
---|---|
Beschorner, U; Böhme, T; Bürgelin, K; Jacques, B; Neumann, FJ; Noory, E; Nührenberg, T; Zeller, T | 1 |
Bae, GH; Choi, ST; Jung, J; Kang, JM; Ko, DS | 1 |
Burov, AI; Bushueva, EV; Griaznov, OG; Lysenko, ER | 1 |
Ishii, H; Koyama, A; Morishima, I; Morita, Y; Murohara, T; Nishikawa, R; Shimamura, K; Takagi, K; Tanaka, A; Tokuda, T; Yamada, T; Yoshioka, N | 1 |
Ando, H; Diaz-Cartelle, J; Fujihara, M; Horie, K; Iida, O; Kawasaki, D; Kozuki, A; Mori, S; Nakamura, S; Soga, Y; Suzuki, K; Urasawa, K; Yamamoto, Y | 1 |
Aschenbach, R; Ingwersen, M; Lehmann, T; Platzer, S; Scheinert, D; Teichgräber, U; Zeller, T | 1 |
Almonacid Popma, A; Deckers, S; Liistro, F; Micari, A; Shishehbor, MH; Weinberg, I | 1 |
Fernandez, EJ; Fujihara, M; Guo, J; Iida, O; Kawasaki, D; Nakamura, M; Saito, S; Soga, Y; Urasawa, K; Yokoi, H | 1 |
Anand, SS; Bauersachs, RM; Beckman, JA; Berkowitz, SD; Bonaca, MP; Brackin, T; Capell, WH; Debus, ES; Fanelli, F; Govsyeyev, N; Haskell, LP; Hess, CN; Hiatt, WR; Mauri, L; Muehlhofer, E; Nehler, MR; Patel, MR; Secemsky, EA; Yeh, RW | 1 |
Gemeinhardt, O; Scheller, B; Schnorr, B; Speck, U | 1 |
Bertges, DJ; Eldrup-Jorgensen, J; Lottes, AE; Majithia, A; Malone, M; Marinac-Dabic, D; Resnic, FS; Robbins, S; Smale, J; Ssemaganda, H | 1 |
Katsanos, K | 1 |
Bi, W; Fu, W; Guo, P; Guo, W; Jia, S; Jia, X; Liu, J; Sun, G; Wang, F; Wang, S; Wu, D; Zhang, J; Zhao, Y; Zhuang, B | 1 |
Conte, MS; Iannuzzi, JC; Sanders, KM; Schneider, PA | 1 |
Matsumoto, Y; Morino, Y; Torii, S | 1 |
Brodmann, M; Faries, PL; Jain, A; Krishnan, P; Lyden, SP; Niazi, KAK; Sachar, R; Sood, A; Werner, M | 1 |
Hata, Y; Iida, O; Ishihara, T; Mano, T; Nakao, S; Nanto, K; Okamoto, S; Takahara, M; Tsujimura, T | 1 |
Gumber, D; Kakkar, A; Karamanis, D; Mathai, SV; Palaiodimos, L; Rivera, A; Safiriyu, I; Shah, A; Sokol, S | 1 |
Argyriou, A; Bisdas, T; Damerau, S; Stavroulakis, K; Torsello, G; Tsilimparis, N | 1 |
Abu Bakr, N; Donas, KP; Kazemtash, M; Muñoz Castellanos, J; Pitoulias, GA; Taneva, GT | 1 |
Chiesa, R; Commeau, P; Cremonesi, A; Garot, P; Honton, B; Kahlberg, A; Langhoff, R; Marone, EM; Sauguet, A; Scheinert, D; Steiner, S; Thieme, M; Zeller, T | 1 |
Choke, ETC; Tang, TY; Wang, JCC; Wong, JCL | 1 |
Amaral, C; Correia, R; Ferreira, ME; Ferreira, RS; Gonçalves, FB; Ribeiro, TF | 1 |
Coscas, R; Jayet, J | 1 |
Angioli, P; Bolognese, L; Ducci, K; Falsini, G; Liistro, F; Pieroni, M; Reccia, MR; Scatena, A; Ventoruzzo, G | 2 |
Aschenbach, R; Beschorner, U; Lehmann, T; Scheinert, D; Teichgräber, U; Thieme, M; Zeller, T | 2 |
Chengjia, Q; Chenyang, S; Jie, F; Lequn, T; Xinnong, L; Yongbao, Z | 1 |
Cui, K; Li, L; Zhao, S | 1 |
McDermott, M; NguyenPho, A; Oktem, B; Tran, M; Wickramasekara, S; Woolford, S; Yoda, C | 1 |
Barry, IP; Brodmann, M; Dahm, J; Macarulay, R; Moscovic, M; Mwipatayi, BP; Tepe, G; Troisi, N; Wong, J; Zeller, T | 1 |
Barco, S; Engelberger, RP; Grigorean, A; Held, U; Holy, E; Kucher, N; Leeger, C; Münger, M; Périard, D; Probst, E; Sebastian, T; Spescha, R; Voci, D | 1 |
Arakawa, M; Hayakawa, N; Hirano, S; Ichihara, S; Inoguchi, Y; Kanagami, T; Kanda, J; Kodera, S; Shakya, S; Takanashi, K | 1 |
Geisler, BP; Lookstein, RA; Lyden, SP; Manda, B; Misra, S; Pflederer, TA; Pietzsch, JB | 1 |
Chen, X; Wang, J; Zhang, WW; Zhao, J | 1 |
Schermerhorn, M; Secemsky, EA; Song, Y; Yeh, RW | 1 |
Bair, EC; Cooper, NT; Elmore, JR; Greif, BA; Lewis, AJ; Major, M; McCarver, BC; Ryer, EJ; Salzler, GG; Wang, S | 1 |
Ansel, GM; Brodmann, M; Choi, D; Menk, J; Micari, A; Scheinert, D; Tepe, G; Zeller, T | 1 |
Cai, H; Dong, J; Lu, S; Song, Q; Ye, Y | 1 |
Halonen, J; Hartikainen, J; Kalbus, V; Kärkkäinen, JM; Kettunen, M; Koivusalo, K; Saari, P; Wallin, W | 1 |
Cui, F; Huang, F; Wei, F | 1 |
Brodmann, M; Guetl, K; Lansink, W; Menk, J; Micari, A; Zeller, T | 1 |
Aschenbach, R; Beschorner, U; Ingwersen, M; Lehmann, T; Platzer, S; Scheinert, D; Teichgräber, U; Zeller, T | 1 |
Kogame, N; Nakamura, M; Saito, S; Utsunomiya, M; Yazaki, Y | 1 |
Christensen, L; Jones-Miller, S; Purushottam, B; Shammas, G; Shammas, NW; Shammas, WJ; Weakley, D | 1 |
Brodmann, M; Diaz-Cartelle, J; Holden, A; Keirse, K; Krishnan, P; Lopez, L; Rao, V; Sachar, R; Schroë, H; Soga, Y; Werner, M | 1 |
Hukauf, M; Kabelitz, M; Pflug, T; Scheinert, D; Schmidt, A; Steiner, S; Wittig, T | 1 |
Astete, CE; Boldor, D; Craciun, I; Dugas, TR; Gorman, JD; Jennings, MH; Sabliov, CM | 1 |
Khashram, M; Teraa, M | 1 |
Bugurov, SV; Cheban, AV; Gostev, AA; Ignatenko, PV; Karpenko, AA; Osipova, OS; Rabtsun, AA; Saaya, SB | 1 |
Brodmann, M; Brunet, J; Déglise, S; Deloose, K; Ducasse, E; Gouëffic, Y; Hendriks, J; Keirse, K; Lansink, W; Levent, K; Maene, L; Sauguet, A; Vandael, F; Verbist, J; Werner, M | 1 |
Ando, K; Brodmann, M; Doros, G; Farhan, S; Iida, O; Kamran, H; Krishnan, P; Laird, J; Micari, A; Sachar, R; Scheinert, D; Schneider, P; Tarricone, A; Tepe, G; Urasawa, K; Yokoi, H; Zeller, T | 1 |
Koyama, A; Morishima, I; Morita, Y; Nishikawa, R; Shimamura, K; Tokuda, T; Yamada, T; Yoshioka, N | 1 |
Yin, G; Zhang, C | 1 |
Beschorner, U; Blessing, E; Brechtel, K; Brucks, S; Euringer, W; Langhoff, R; Maiwald, L; Popescu, C; Scheinert, D; Schellong, S; Schmidt, A; Schröder, H; Schuster, J; Steiner, S; Tepe, G; Thieme, M; Weiss, N; Wittig, T; Zeller, T | 1 |
Morrison, JT; Valle, JA | 1 |
Doijiri, T; Hishikari, K; Honda, Y; Ito, Y; Kobayashi, N; Mori, S; Tobita, K; Tsutsumi, M; Yamauchi, Y; Yamawaki, M | 1 |
Ando, K; Brodmann, M; Iida, O; Jain, A; Krishnan, P; Laird, JR; Rocha-Singh, KJ; Scheinert, D; Schneider, PA; Shishehbor, MH; Tepe, G; Zeller, T | 1 |
Choi, D; Do, YS; Ko, YG; Kum, S; Lee, SW; Menk, JS; Rha, SW; Won, JH | 1 |
Beschorner, U; Böhme, T; Molitor, M; Neumann, FJ; Noory, E; Nührenberg, T; Zeller, T | 1 |
Hillegass, WB; Winscott, JG | 2 |
Bianchini Massoni, C; Epifani, E; Freyrie, A; Gasbarro, V; Paladini, I; Strozzi, F; Tusini, N; Ucci, A; Zenunaj, G | 1 |
Cho, JS; Colvard, B; Kashyap, VS; Kumins, NH; Smith, JA; So, KL | 1 |
Chen, X; Dong, H; Fu, W; Huang, X; Jiang, W; Li, X; Lu, X; Wang, H; Yang, J; Yue, J | 1 |
Aydın, C; Demirkıran, A; Özpak, HB | 1 |
Christensen, L; Jones-Miller, S; Shammas, G; Shammas, NW | 1 |
Almeida, RS; Alvim Fiorelli, RK; Belczac, SQ; Dalio, MB; Gutfilen, B; Joviliano, EE; Oliveira, R; Peclat de Oliveira, JC; Peclat de Oliveira, LM; Rolim Maia Peclat, AP | 1 |
Bertges, DJ; Dani, SS; Eldrup-Jorgensen, J; Joynt Maddox, KE; Levy, M; Majithia, A; Matheny, M; Resnic, F; Robbins, S; Secemsky, E; Sedrakyan, A; Siami, FS; Ssemaganda, H | 1 |
Heller, MB; Lam, A; Wu, X; Youm, J; Zhou, AL | 1 |
Abebe, B; Finn, AV; Ghosh, SKB; Kawai, K; Kawakami, R; Kolodgie, FD; Konishi, T; Romero, ME; Sato, Y; Virmani, R; Vozenilek, AE | 1 |
Fujita, T; Haraguchi, T; Kashima, Y; Otake, R; Sato, K; Tsujimoto, M | 1 |
Bosiers, M; Bosiers, MJ; Callaert, J; DE Donato, G; Deloose, K; Eckstein, HH; Galvagni Silveira, P; Giaquinta, A; Hendriks, J; Keirse, K; Maene, L; Navarro, T; Scheinert, D; Tessarek, J; Torsello, G; van den Eynde, W; Verbist, J; Veroux, P; Wahl-Gravsen, J | 1 |
Beschorner, U; Böhme, T; Brechtel, K; Lichtenberg, M; Müller-Hülsbeck, S; Noory, E; Piorkowski, M; Tepe, G; Thieme, M; Zeller, T | 1 |
Angel de Gregorio, M; Brodmann, M; Manteca, JC; Munoz Ruiz-Canela, JJ; Ruiz, EM; Salmeron, RR; Tepe, G; Trujillo, IG | 1 |
Fanelli, F; Haage, P; Hamady, M; Loffroy, R; Morgan, RA; Müller-Hülsbeck, S; O'Sullivan, G; Wolf, F | 1 |
Dou, KF; Li, JJ; Qian, J; Yang, C | 1 |
Tepe, G | 1 |
Iijima, R; Nakamura, M; Saito, S; Utsunomiya, M; Yokouchi, Y | 1 |
Bosiers, M; Bosiers, MJ; Callaert, J; De Donato, G; Deloose, K; Eckstein, HH; Giaquinta, A; Hendriks, J; Keirse, K; Maene, L; Navarro, T; Scheinert, D; Silveira, PG; Teβarek, J; Torsello, G; van den Eynde, W; Verbist, J; Veroux, P | 1 |
Teichgräber, U | 1 |
Fanelli, F; Haage, P; Hamady, M; Loffroy, R; Morgan, RA; Müller-Hülsbeck, S; O'Sullivan, G; Slijepčević, B; Wolf, F | 1 |
Biondi-Zoccai, G; Giordano, A; Spadafora, L | 1 |
Ansari, MM; Armstrong, E; Arroyo, M; Couch, K; Fujihara, M; Geraghty, PJ; Gouëffic, Y; Iida, O; Jaff, MR; Mathews, SJ; Mustapha, JA; Nakama, T; Nakamura, M; Ohura, N; Pinto, DS; Rao, S; Soga, Y; van Overhagen, H; Weinberg, I | 1 |
Chen, Y; Di, X; Fu, Y; Lai, Z; Liu, B; Liu, C; Liu, Z; Ni, L; Shao, J; Song, X; Ye, W; Zeng, R; Zheng, Y | 1 |
Ingwersen, M; Teichgräber, UK | 1 |
Rissanen, TT | 1 |
Gray, WA; Mullin, CM; Parikh, SA; Rogers, T; Schneider, PA | 1 |
Ates, I; Avci, R; Cilingiroglu, M; Dijkstra, J; Feldman, MD; Hoyt, T; Iliescu, C; Kose, G; Lendel, V; Marmagkiolis, K; McElroy, A; McIntosh, V; Mego, D; Milner, TE; Okutucu, S; Paixao, A; Park, J; Shaar, M | 1 |
Ando, K; Fujihara, M; Iida, O; Katsuki, T; Kawasaki, D; Okamoto, S; Soga, Y; Takahara, M | 1 |
Acín, F; Alonso, M; de Blas, MJ; Giménez-Gaibar, A; Riambau, V | 1 |
Gad, MM; Karrthik, AK; Mahmoud, AA; Mahmoud, AN | 1 |
Ansel, GM; Bosiers, M; Dake, MD; Holden, A; Iida, O; Jaff, MR; Lottes, AE; O'Leary, EE; Saunders, AT; Schermerhorn, M; Yokoi, H; Zeller, T | 1 |
Anderson, JA; Engebretson, D; Evans, R; Fuglsby, K; Kelly, P; Lamichhane, S; Pohlson, K; Remund, T | 1 |
Adelman, MA; Ansel, GM; Brodmann, M; Gray, WA; Jaff, MR; Krishnan, P; Lyden, SP; Ouriel, K; Parikh, SA; Razavi, MK; Vermassen, F; White, R; Zeller, T | 1 |
Adelman, MA; Brodmann, M; Clair, DG; Geraghty, P; Lee, A; Ouriel, K; Peña, C; Rosenfield, K; Scheinert, D; White, R | 1 |
Faldum, A; Freisinger, E; Gerss, J; Goerlich, D; Koeppe, J; Malyar, NM; Marschall, U; Reinecke, H | 1 |
Banerjee, S; Fehder, D; Fry, ETA; Ginor, R; Kothapalli, P; Monteleone, PP; Pirwitz, MJ; Stern, AD; Vollmar, D | 1 |
Hinnen, JW; Koning, O; Nugteren, M; Scholtes, V; Serné, A; van den Haak, R; Verhoeven, B | 1 |
Baumgartner, I; Bernhard, SM; Dopheide, JF; Drexel, H; Haine, A; Lenz, A; Schindewolf, M; Schmid, MJ | 1 |
Aschenbach, R; Beschorner, U; Blessing, E; Brechtel, K; Brucks, S; Klumb, CT; Lehmann, T; Lichtenberg, M; Scheinert, D; Sixt, S; Teichgräber, U; Thieme, M; Zeller, T | 1 |
Desai, M | 1 |
Alvandi, B; Armstrong, EJ; Behan, S; Foley, TR; Giannopoulos, S; Hossain, P; Jawaid, O; Kokkinidis, DG; Singh, GD; Waldo, SW | 1 |
Konijn, LCD; Maessen, MFH; Mali, WPTM; Spreen, MI; Statius van Eps, RG; van Dijk, LC; van Herpen, NPC; van Overhagen, H; Veger, HT; Wakkie, T; Wever, JJ | 1 |
Duval, S; Rocha-Singh, KJ | 1 |
Baber, U; Bittl, JA; Feldman, RL; He, Y; Kaul, S; von Mering, GO | 1 |
Carnevale, M; Garg, K; Lipsitz, EC; Phair, J; Scher, L; Shariff, S | 2 |
Caradu, C; Ducasse, E | 1 |
de Vries, JPM; Huizing, E; Ipema, J; Schreve, MA; Ünlü, Ç | 1 |
Ambani, RN; Bose, S; Cho, JS; Harth, KC; Kashyap, VS; King, AH; Kumins, NH; Li, J; Shishehbor, MH; Thomas, JP; Wong, VL | 1 |
Behrendt, CA; Bertges, DJ; Debus, ES; Kölbel, T; Kreutzburg, T; L'Hoest, H; Larena-Avellaneda, A; Peters, F; Schermerhorn, M; Sedrakyan, A | 1 |
Anderson, JA; Engebretson, D; Fuglsby, K; Lamichhane, S | 1 |
Blessing, E; Brechtel, K; Brucks, S; Euringer, W; Langhoff, R; Maiwald, L; Scheinert, D; Schellong, S; Schmidt, A; Schröder, H; Schuster, J; Steiner, S; Tepe, G; Thieme, M; Ulrich, M; Weiss, N; Zeller, T | 1 |
Binkert, CA; Brodmann, M; Christensen, JK; Corpataux, JM; Keirse, K; Moscovic, M; Nano, G; Schroeder, H; Tepe, G; Zeller, T | 2 |
Babaev, A; Bachinsky, W; Diaz-Cartelle, J; Golzar, J; Gray, WA; Iida, O; Kawasaki, D; Müller-Hülsbeck, S; Park, J; Prem, JT; Soga, Y; Vermassen, F | 1 |
Bosiers, M; Callaert, J; De Donato, G; Deloose, K; Eckstein, HH; Giaquinta, A; Hendriks, J; Keirse, K; Maene, L; Navarro, T; Scheinert, D; Setacci, C; Silveira, PG; Teβarek, J; Torsello, G; Veroux, P; Wauters, J | 1 |
Aggarwala, G; Bunch, F; Dippel, E; Kassab, E; Khan, MA; LeCroy, C; McClure, JM; Nair, P; Tolleson, T; Walker, C | 1 |
Dan, K; Garcia-Garcia, HM; Hideo-Kajita, A; Khalid, N; Kolm, P; Shlofmitz, E; Torguson, R; Waksman, R; Wermers, JP | 1 |
Fang, L; Lai, Z; Lei, J; Li, K; Liu, B; Liu, X; Shao, J; Wang, J; Xu, L; Yu, X; Zhang, X | 1 |
Dinh, K; Gomes, ML; Holden, A; Paravastu, SCV; Schneider, PA; Thomas, SD; Varcoe, RL | 1 |
Beck, AW; Bertges, DJ; Cronenwett, JL; Eldrup-Jorgensen, J; Eslami, MH; Goodney, PP; Schermerhorn, M; Sedrakyan, A; Sun, T | 1 |
Banyai, M; Baumgartner, I; Bosiers, M; Brodmann, M; Micari, A; Scheinert, D; Shishehbor, MH; Vermassen, FEG; Wang, H; Zeller, T | 1 |
Commeau, P; Desgranges, P; Ducasse, E; Feugier, P; Gouëffic, Y; Guyomarc'h, B; Hoffmann, CT; Kaladji, A; Leclere, B; Lermusiaux, P; Maurel, B; Pernès, JM; Rosset, E; Salomon du Mont, L; Sauguet, A | 1 |
Ando, K; Fujihara, M; Iida, O; Kawasaki, D; Kuramitsu, S; Soga, Y; Tomoi, Y | 1 |
Aschenbach, R; Beschorner, U; Blessing, E; Brechtel, K; Brucks, S; Erbel, C; Heilmeier, B; Klumb, CT; Lehmann, T; Lichtenberg, M; Riambau, V; Scheinert, D; Sixt, S; Teichgräber, U; Thieme, M; von Flotow, P; Werk, M; Wienke, A; Zeller, T | 1 |
Stanek, F | 1 |
Cawthon, CV; Christians, U; Erwin, M; Fedor, N; Geary, RL; Goel, E; Rayl, T; Register, TC; Saul, J; Schaff, C; Wilson, O; Yazdani, SK | 1 |
Azar, D; Jabbarzadeh, E; Kolachalama, VB; Lott, JT; Shazly, T | 1 |
Barrett, B; Doyle, M; Gullipalli, R; Linehan, V | 1 |
Di Mario, C; Liistro, F | 1 |
Ansel, GM; Beckman, JA; Duval, S; Edelman, ER; Granada, JF; Ioannidis, JPA; Jaff, MR; Lyden, SP; Misra, S; Mullin, CM; Rocha-Singh, KJ; Schneider, PA; Tzafriri, AR; White, CJ | 1 |
Batchelder, A; Davies, R; Diamantopoulos, A; Lea, T; Saha, P; Saratzis, A; Saratzis, N; Thomson, B; Yap, T; Zayed, H | 1 |
Chakraborty, A; Royce, S; Zhao, Y | 1 |
Gomes, ML; Katib, N; Narroway, HG; Thomas, SD; Varcoe, RL | 1 |
Benko, A; Brodmann, M; Choi, D; Dobranszki, R; Guo, J; Jaff, MR; Micari, A; Stavroulakis, K; Tepe, G; Torsello, G; Vermassen, FEG; Veroux, P; Zeller, T | 1 |
Gray, WA; Vanderland, M | 1 |
Beschorner, U; Böhme, T; Bürgelin, K; Cheung, F; Gebauer, E; Jacques, B; Lechner, P; Macharzina, R; Noory, E; Nührenberg, T; Zeller, T | 1 |
Jaff, MR; Kobe, DS; Schneider, PA; Shishehbor, MH; Zeller, T | 1 |
Bertges, DJ; Malas, MB; Mathlouthi, A; Naazie, I; Yei, KS | 1 |
Castriota, F; Cremonesi, A; Micari, A; Nerla, R | 1 |
Anzai, H; Bangalore, S; Kuno, T; Mikami, T; Numasawa, Y; Takagi, H; Ueyama, H | 1 |
Barsness, GW; Greenberg-Worisek, AJ; Gulati, R; Misra, S; Vallabhajosyula, S; Windebank, AJ | 1 |
Akahori, H; Imanaka, T; Ishihara, M; Kimura, T; Miki, K; Tanaka, T; Yanaka, K; Yoshihara, N | 1 |
Ambani, RN; Bose, S; Cho, JS; Colvard, B; Harth, KC; Kashyap, VS; King, AH; Kumins, NH; Thomas, JP; Wong, VL | 2 |
Allmendinger, AC; Anton, S; Barkhausen, J; Goltz, JP; Jacob, F; Planert, M; Stahlberg, E | 1 |
Behrendt, CA; Debus, ES; Heidemann, F; Kreutzburg, T; Kuchenbecker, J; L'Hoest, H; Marschall, U; Peters, F; Sedrakyan, A | 1 |
Ansel, G; Brodmann, M; Gao, Q; Krishnan, P; Laird, J; Mauri, L; Micari, A; Ouriel, K; Schneider, PA; Shishehbor, MH; Soga, Y; Zeller, T | 1 |
Kavala, AA; Kuserli, Y; Turkyilmaz, S | 1 |
Iida, O; Jaff, MR; Ookubo, H; Saito, S; Soga, Y; Urasawa, K; Wang, H; Yokoi, H | 1 |
Beelen, R; Bosiers, M; Deloose, K; Hendriks, J; Keirse, K; Lauwers, P; Maene, L; Peeters, P; Verbist, J; Verschueren, M; Wauters, J | 1 |
Leng, R; Li, CM; Ren, HL; Wang, Q; Zhang, WD; Zhu, RM | 1 |
Beschorner, U; Böhme, T; Bürgelin, K; Cheung, F; Jacques, B; Macharzina, R; Neumann, FJ; Noory, E; Nührenberg, T; Zeller, T | 1 |
Brodmann, M; Christensen, JK; Corpataux, JM; Dahm, J; Ghotbi, R; Keirse, K; Moscovic, M; Nano, G; Tepe, G; Wang, JCC; Zeller, T | 1 |
Angioli, P; Bolognese, L; Ducci, K; Falsini, G; Liistro, F; Pieroni, M; Reccia, MR; Ricci, L; Scatena, A; Ventoruzzo, G | 1 |
Björkman, P; Venermo, M; Weselius, EM | 1 |
Ansel, GM; Dake, MD; Fanelli, F; Fu, W; Iida, O; Jiang, X; Lottes, AE; O'Leary, EE; Reichert, H; Schermerhorn, M; Zeller, T; Zen, K | 1 |
Guzman, RJ; Kim, TI; Kiwan, G; Mena-Hurtado, C; Mohamedali, A; Mojibian, H; Ochoa Chaar, CI; Zhang, Y | 1 |
Chandra, V; Harris, EJ; Lee, JT; Stern, JR; Tran, K | 1 |
Dake, MD; Kichikawa, K; Komori, K; Lottes, AE; Nakamura, M; Nanto, S; O'Leary, EE; Ohki, T; Saunders, AT; Sugimoto, M; Yokoi, H | 1 |
Asada, H; Fujiwara, R; Higuchi, K; Isawa, K; Kijima, Y; Kozuki, A; Miyata, T; Nagoshi, R; Sakamoto, Y; Seo, H; Shibata, H; Shimizu, M; Shite, J; Soga, F; Suzuki, A; Takahara, M | 1 |
Beschorner, U; Böhme, T; Bürgelin, K; Jacques, B; Kuhn, LM; Macharzina, R; Neumann, FJ; Noory, E; Nührenberg, T; Zeller, T | 1 |
Dai, X; Huang, X; Jiang, M; Liu, C; Liu, Z; Ye, W; Zhang, X | 1 |
Bertges, DJ; Erickson, CA; Farb, A; Fox, ML; Jiang, JH; Krucoff, MW; Lin, AY; Lottes, AE; Malone, ML; Papandreou, G; Rosenfield, K; Royce, SM; Wang, L; Whatley, EM; Wilgus, RW | 1 |
Cilingiroglu, M; Kilic, ID | 1 |
Babaev, A; Benko, A; Diaz-Cartelle, J; Dulas, DD; Fujihara, M; Gray, WA; Iida, O; Müller-Hülsbeck, S; O'Connor, D; Soga, Y; Zeller, T | 1 |
Andersson, M; Danielsson, P; Delle, M; Engström, J; Falkenberg, M; Fransson, T; Gillgren, P; Hamoud, M; Hilbertson, A; James, S; Johansson, P; Karlsson, L; Kragsterman, B; Lindgren, H; Ludwigs, K; Mellander, S; Nordanstig, J; Nyman, N; Öjersjö, A; Renlund, H; Sigvant, B; Skoog, P; Starck, J; Tegler, G; Toivola, A; Truedson, M; Wahlgren, CM; Wallinder, J | 1 |
Annapureddy, A; Aronow, HD; Curtis, JP; Jelani, QU; Jones, WS; Mena-Hurtado, C; Patel, MR; Secemsky, EA; Shishehbor, MH; Tsai, TT; Wang, Y; Weissler, EH | 1 |
Bobka, T; Chen, W; Dyniewski, B; Kraemer, C; Tan, TW; Zhou, W | 1 |
Barrette, E; Bockstedt, L; Bonaca, MP; Hanson, T; Hess, CN; Manda, B; Monteiro, J; Secemsky, EA; Yeh, RW | 1 |
Fujihara, M; Iida, O; Katsuki, T; Kawasaki, D; Kozuki, A; Mano, T; Soga, Y; Takahara, M; Tsujimura, T | 1 |
Albaghdadi, MS; Armstrong, EJ; Aronow, HD; Beyer, SE; Carroll, BJ; Gurin, MI; Parikh, SA; Secemsky, EA; Weinberg, M; Yeh, R | 1 |
Ando, H; Doijiri, T; Habara, M; Haraguchi, T; Hayashi, T; Imoto, Y; Kamoi, D; Kimura, M; Nakama, T; Sakamoto, H; Sato, T; Sato, Y; Sugihara, M; Tan, M; Tsubakimoto, Y; Urasawa, K | 1 |
Farb, A; Maisel, WH; Malone, M | 1 |
Bi, W; Fu, W; Guo, P; Guo, W; Jia, X; Liu, J; Wang, F; Wang, S; Wu, D; Xu, Y; Zhang, J; Zhao, Y; Zhuang, B | 1 |
Guo, G; Wang, Y; Yang, L; Zhang, T | 1 |
Kibbe, MR; McDermott, MM | 1 |
Buszman, PE; Buszman, PP; Granada, JF; Hrycek, E; Kachel, M; Kaźmierczak, P; Kiesz, RS; Ludyga, T; Milewski, KP; Nowakowska, I; Nowakowski, P; Polczyk, F; Uchto, W; Żurakowski, A | 1 |
Hazenberg, CE; Huizing, E; Ipema, J; Kum, S; Lim, D; Lok, IY; Tan, YK; Ünlü, Ç | 1 |
Argyriou, A; Bisdas, T; Bosiers, M; Stavroulakis, K; Torsello, G; Tsilimparis, N | 1 |
Krawisz, AK; Secemsky, EA | 1 |
Alós, J; Arjumand, J; Härtel, D; Hohl, C; Korosoglou, G; Langhoff, R; Martínez, E; Raut, W; Reimer, P; Riazi, H; Romani, S; Schmidt, A; Waliszewski, M; Yahya, SA | 1 |
Katsanos, K; Kitrou, P; Spiliopoulos, S | 1 |
Bi, W; Fu, W; Guo, P; Guo, W; Liu, J; Ren, H; Wang, F; Wang, S; Wu, D; Zhang, J; Zhao, Y; Zhuang, B | 1 |
Bajardi, G; Dinoto, E; Ferlito, F; Mirabella, D; Pakeliani, D; Pecoraro, F | 1 |
Ikeda, K; Nakamura, M; Suzuki, Y; Takata, M; Ueno, T; Yamaguchi, T; Yokoi, H | 1 |
Katsanos, K; Spiliopoulos, S | 1 |
Schermerhorn, M; Secemsky, EA; Shen, C; Yeh, RW | 1 |
Ansari, MM; Brodmann, M; Diaz-Cartelle, J; Kozuki, A; Lopez, L; Ramanath, VS; Sachar, R; Schroë, H; Soga, Y; Zeller, T | 1 |
Bausback, Y; Bosiers, M; Brucks, S; Peeters, P; Scheinert, D; Schmidt, A; Steiner, S; Wittig, T; Zeller, T | 1 |
Kodani, E | 1 |
Ansel, G; Baeriswyl, JL; DeRubertis, BG; Garcia, LA; Krishnan, P; Nolte-Ernsting, CCA; Rocha-Singh, KJ; Rosenfield, K; Sachar, R; Scott, EC; Winscott, JG; Zeller, T | 1 |
Bernardo, NL; Case, BC; Craig, PE; Forrestal, BJ; Torguson, R; Waksman, R; Yerasi, C; Zhang, C | 1 |
Chen, AZL; Dinh, K; Holden, A; Limmer, AM; Schneider, PA; Thomas, SD; Varcoe, RL | 1 |
Altaf, N; Ariyaratne, TV; Deltetto, I; El-Hoss, J; Mwipatayi, BP; Peacock, A; Taylor, C; Thomas, S | 1 |
Eisenberg, N; Mafeld, S; Rajan, DK; Roche-Nagle, G; Wang, G; Warren, BE; Zhu, J | 1 |
Burgmans, MC; Chan, ES; Chan, SXJM; Chng, SP; Chong, TT; Damodharan, K; Gogna, A; Irani, FG; Kwan, J; Leong, S; Patel, A; Pua, U; Quek, LHH; Tan, BP; Tan, BS; Tan, GWL; Tay, KH; Too, CW; Yuan, W; Zhuang, KD | 1 |
Hendgen-Cotta, U; Jánosi, RA; Johnstone, M; Lortz, J; Manzke, A; Petrikhovich, O; Rammos, C; Rassaf, T; Steinmetz, M | 1 |
Diaz-Cartelle, J; Fujihara, M; Gray, WA; Iida, O; Kawasaki, D; Kichikawa, K; Miyamoto, A; Mori, S; Müller-Hülsbeck, S; Nakamura, M; Ohki, T; Soga, Y; Yokoi, H | 1 |
Case, BC; Torguson, R; Waksman, R; Zhang, C | 1 |
Bisdas, T; Björkman, P; de Boer, S; Del Giudice, C; Karnabatidis, D; Katsanos, K; Kitrou, P; Krokidis, M; Spiliopoulos, S; Teichgräber, U | 1 |
Beelen, R; Bosiers, M; Callaert, J; Deloose, K; Hendriks, JMH; Keirse, K; Maene, L; Peeters, P; Verbist, J | 1 |
Castriota, F; Cremonesi, A; Grattoni, C; Liso, A; Micari, A; Nerla, R; Pantaleo, P; Roscitano, G; Russo, P; Vadalà, G | 1 |
Bijlstra, OD; de Borst, GJ; de Vries, JPM; Knippenberg, B; Mali, WPTM; Martens, JM; Spreen, MI; Statius van Eps, RG; van Dijk, LC; van Overhagen, H; Vonken, EPA; Vos, JA; Wever, JJ | 1 |
Cassese, S; Dewitz, K; Fusaro, M; Groha, P; Hadamitzky, M; Hiendlmayer, R; Ibrahim, T; Kastrati, A; Kufner, S; Laugwitz, KL; Ott, I; Schunkert, H; Steppich, B | 1 |
Brodmann, M; Jaff, MR; Krüger, K; Meyer, DR; Reimer, P; Schroeder, H; Werner, M | 1 |
Burrows, SA; Daneshmand, A; Daniel, R; Mwipatayi, BP; Perera, K; Thomas, SD; Wong, J | 1 |
Cheng, Y; Conditt, GB; Gasior, P; Granada, JF; Kaluza, GL; McGregor, J; Valencia, AF | 1 |
Dake, MD; Kichikawa, K; Komori, K; Lottes, AE; Nakamura, M; Nanto, S; O'Leary, EE; Ogawa, Y; Ohki, T; Saunders, AT; Yokoi, H | 1 |
Huynh, K | 1 |
Bausback, Y; Del Giudice, C; Diaz-Cartelle, J; Geist, V; Lichtenberg, M; Marx, C; Sauguet, A; Scheinert, D; Schult, I; Sievert, H; Ströbel, A; Willfort-Ehringer, A | 1 |
Albrecht, T; Gögebakan, Ö; Halloul, Z; Meyer, DR; Müller-Hülsbeck, S; Ott, I; Redlich, U; Ricke, J; Schnorr, B; Tautenhahn, J; Tepe, G; Waliszewski, M; Zeller, T | 1 |
Bunch, F; Carr, J; Kassab, E; Walker, C | 1 |
Bachinsky, WB; Brodmann, M; Cardenas, J; Faries, P; Holden, AH; Jaff, MR; Jain, A; Krishnan, P; Lyden, SP; Mena-Hurtado, C; Mustapha, JA; Niazi, K; Sachar, R; Werner, M | 1 |
Cassese, S; Dewitz, K; Fusaro, M; Groha, P; Hadamitzky, M; Ibrahim, T; Kasel, AM; Kastrati, A; Kufner, S; Laugwitz, KL; Ott, I; Schunkert, H; Steppich, B; Voll, F; Wittmann, T | 1 |
Duda, S; Lux, B; Martorana, M; Meyer, DR; Miller, LE; Ruecker, F; Schroeder, H | 1 |
Böckler, D; Bosma, GPT; Bouwman, LH; de Boer, SW; de Leeuw, B; de Vries, JPM; de Vries-Werson, DAB; Dovzhanskiy, DI; Elgersma, OE; Fioole, B; Heyligers, JMM; Hissink, RJ; Hooijboer, PGA; Tutein Nolthenius, RP; van den Heuvel, DAF; Vink, TWF; Vos, FWF; Vos, JA; Vroegindeweij, D | 1 |
Anderson, J; Danielson, L; Kelly, P; Laurich, C; Mani, G; Pohlson, K; Remund, T; Santos, A; Schultz, G; Shermann, A | 1 |
Edelman, ER; Garcia-Polite, F; Knutson, J; Kohler, R; Markham, P; Muraj, B; Nikanorov, A; Stanley, J; Tzafriri, AR; Zani, B | 1 |
Boesmans, E; Defraigne, JO; Deloge, C; Van Damme, H | 1 |
Amann-Vesti, B; Blessing, E; Jaff, MR; Krzanowski, M; Langhoff, R; Peeters, P; Rocha-Singh, KJ; Scheinert, D; Sixt, S; Tepe, G; Torsello, G; Zeller, T | 1 |
Diaz-Cartelle, J; Keirse, K; Müller-Hülsbeck, S; Schroë, H; Zeller, T | 2 |
Breuckmann, F; Briner, L; Grell, H; Lichtenberg, M; Niemöller, K; Ranft, J; Rassaf, T; Saucy, F; von Bilderling, P | 1 |
Altit, R; Gray, WA | 1 |
Brodmann, M; Jaff, MR; Keirse, K; Li, P; Scheinert, D; Schmahl, R; Spak, L; Zeller, T | 1 |
Blessing, E; Goueffic, Y; Holden, AH; Ito, W; Jaff, MR; Jansen, SJ; Keirse, K; Micari, A; Peeters, P; Schroë, H; Vermassen, F; Zeller, T | 1 |
Astarci, P; Elens, M; Lacroix, V; Mastrobuoni, S; Possoz, J; Verhelst, R | 1 |
Cipollari, S; Dake, MD; Kichikawa, K; Komori, K; Lottes, AE; Nakamura, M; Nanto, S; O'Leary, EE; Ohki, T; Saunders, AT; Yokoi, H | 1 |
Hawkins, BM; Hooker, JB | 1 |
Brodmann, M; Hasenbank, MS; Jaff, MR; Krishnan, P; Laird, JR; Metzger, C; Micari, A; Sachar, R; Scheinert, D; Schneider, PA; Tepe, G; Wang, H; Zeller, T | 1 |
Alston, M; Ansel, GM; Collins, C; Falls, A; Kolluri, R; Mohir-Sadaai, S; Patil, N; Phillips, JA; Reid, B; Troyan, M; Whipp, A | 1 |
Del Giudice, C; Diaz-Cartelle, J; Geist, V; Lichtenberg, M; Marx, C; Sauguet, A; Scheinert, D; Schult, I; Sievert, H; Steiner, S; Ströbel, A; Willfort-Ehringer, A | 1 |
Brodmann, M; Frost, M; Keirse, K; Micari, A; Peeters, P; Tepe, G; Wang, H; Zeller, T | 1 |
Argyriou, A; Beropoulis, E; Bisdas, T; Stavroulakis, K; Torsello, G | 1 |
Antoniou, GA; Ballance, L; Cawley, O; Katsogridakis, E | 1 |
Babaev, A; Benko, A; Diaz-Cartelle, J; Gray, WA; Holden, A; Jaff, MR; Keirse, K; Müller-Hülsbeck, S; Popma, J; Prem, JT; Schroeder, H; Soga, Y; Yokoi, Y | 1 |
Cassese, S; Fusaro, M; Kufner, S; Ndrepepa, G; Xhepa, E | 1 |
Brodmann, M; Jaff, MR; Micari, A; Peeters, P; Scheinert, D; Schmahl, R; Tepe, G; Wang, H; Zeller, T | 1 |
Dake, MD; Ichihashi, S; Kichikawa, K; Komori, K; Lottes, AE; Nakamura, M; Nanto, S; O'Leary, EE; Ohki, T; Snyder, SA; Yokoi, H | 1 |
Bi, W; Fu, W; Guo, P; Guo, W; Jia, X; Wang, F; Wang, S; Wu, D; Xu, Y; Zhang, J; Zhao, Y; Zhuang, B | 1 |
Brodmann, M; Granada, JF; Jaff, MR; Krüger, K; Meyer, DR; Reimer, P; Schroeder, H; Werner, M | 1 |
Buszman, PE; Buszman, PP; Dębiński, M; Gąsior, M; Granada, JF; Jelonek, M; Kachel, M; Kiesz, RS; Ludyga, T; Milewski, K; Nowakowski, P; Orlik, B; Polczyk, F; Żurakowski, A | 1 |
Karnabatidis, D; Katsanos, K; Kitrou, P; Krokidis, M; Spiliopoulos, S | 1 |
Ansel, GM; Brodmann, M; Jaff, MR; Keirse, K; Li, P; Micari, A; Peeters, P; Rocha-Singh, KJ; Scheinert, D; Schmahl, R; Tepe, G; Zeller, T | 1 |
Honton, B; Philippart, R; Sauguet, A | 1 |
Ansel, G; Brodmann, M; Doros, G; Gao, Q; Laird, JR; Micari, A; Schneider, PA; Shishehbor, MH; Tepe, G; Zeller, T | 1 |
Giri, J | 1 |
Beckman, JA; Jaff, MR; Krawisz, A; Kundi, H; Mustapha, J; Parikh, SA; Rosenfield, K; Secemsky, EA; Weinberg, I; Yeh, RW | 1 |
Chervenkoff, V; Esposito, G; Gerardi, D; Giugliano, G; Goverde, P; Kotasov, D; Magliulo, F; Stabile, E; Taeymans, K; Trimarco, B; Zhelev, D | 1 |
Jaff, MR; Keirse, K; Li, P; Micari, A; Scheinert, D; Schmahl, R; Tepe, G; Zeller, T | 1 |
Boitet, A; Coggia, M; Coscas, R; Dupont, S; Grassin-Delyle, S; Lamy, E; Louedec, L; Michel, JB | 1 |
Dake, MD; Misra, S | 1 |
Bi, W; Du, X; Fu, WG; Guo, PF; Guo, W; Jia, X; Wang, F; Wang, SM; Wu, DM; Zhang, JW; Zhang, MH; Zhao, Y; Zhuang, BX | 1 |
Holewijn, S; Keirse, K; Lee, SW; Li, P; Micari, A; Reijnen, MMPJ; van Wijck, I; Veroux, P; Voulgaraki, D; Zeller, T | 1 |
Cortese, B; Pellegrini, D | 1 |
Azar, DA; Chang, GH; Chitalia, VC; Kolachalama, VB; Lyle, C; Shazly, T | 1 |
Phillips, J | 1 |
Cheng, Y; Ferrone, M; Granada, JF | 1 |
Veith, FJ | 1 |
Beckman, JA; White, CJ | 1 |
Brodmann, M; Jaff, MR; Krishnan, P; Laird, JA; Masters, M; Metzger, DC; Micari, A; Scheinert, D; Schneider, PA; Tepe, G; Wang, H; Zeller, T | 1 |
Fujii, K; Fukunaga, M; Hirata, KI; Horimatsu, T; Iida, O; Ishihara, T; Kozuki, A; Nanto, S; Otake, H; Shinke, T; Shite, J; Takahara, M; Terashita, D; Tsukiyama, Y; Uematsu, M; Zen, K | 1 |
Conte, MS; Mills, JL; Murad, MH | 1 |
Ando, K; Fujihara, M; Iida, O; Ishihara, T; Kawasaki, D; Soga, Y; Tomoi, Y | 1 |
Adachi, A; Bolstad, F; Fujimura, N; Ichihashi, S; Iwakoshi, S; Kichikawa, K; Kyuragi, R; Nagatomi, S; Obayashi, K; Saeki, K; Shibata, T; Yamamoto, H | 1 |
Dan, K; Garcia-Garcia, HM; Hideo-Kajita, A; Kolm, P; Torguson, R; Waksman, R; Wermers, JP; Zhang, C | 1 |
Brodmann, M; Geraghty, PJ; Jaff, MR; Mustapha, JA; Saab, F; Settlage, RA | 1 |
Beschorner, U; Brechtel, K; Dake, MD; Kultgen, PL; Noory, E; Rastan, A; Tepe, G; Zeller, T | 1 |
Biamino, G; Castriota, F; Cioppa, A; Cremonesi, A; Grattoni, C; Liso, A; Marchese, A; Micari, A; Pantaleo, P; Rubino, P; Vadalà, G | 1 |
Mahmud, E | 1 |
Byrne, RA; Cassese, S; Fusaro, M | 1 |
Günther, RW; Kelm, M; Krombach, GA; Neizel, M; Ruebben, A; Weiss, N | 1 |
Angioli, P; Bellandi, G; Bolognese, L; Ducci, K; Falsini, G; Grotti, S; Liistro, F; Porto, I; Ricci, L; Turini, F; Ventoruzzo, G | 3 |
Beschorner, U; Brechtel, K; Claussen, CD; Scheller, B; Schnorr, B; Speck, U; Tepe, G; Zeller, T | 1 |
Cannavale, A; D'Adamo, A; Fanelli, F; Gazzetti, M | 1 |
Diehm, N; Schneider, H | 1 |
Sternbergh, WC | 1 |
Bosiers, M; Duda, S; Krankenberg, H; Naisbitt, S; Ricke, J; Rosenfield, K; Scheinert, D; Tepe, G; Zeller, T | 1 |
Armstrong, EJ; Laird, JR | 1 |
Carrera, S; San Norberto, EM; Taylor, JH; Vaquero, C | 1 |
Owens, CD | 1 |
Biamino, G; Cioppa, A; Cota, L; Esposito, G; Giugliano, G; Popusoi, G; Pucciarelli, A; Rubino, P; Salemme, L; Stabile, E; Tesorio, T; Trimarco, B; Virga, V | 1 |
Karunanithy, N; Katsanos, K; Krokidis, M; Sabharwal, T; Spiliopoulos, S; Taylor, P | 1 |
Ahmed, I; Diamantopoulos, A; Karunanithy, N; Katsanos, K; Kitrou, P; Padayachee, S; Parthipun, A; Zayed, H | 1 |
Becquemin, JP; Houbballah, R; Leopardi, M | 1 |
Awata, M; Fujita, M; Iida, O; Iida, T; Ishihara, T; Nanto, K; Nanto, S; Okamoto, S; Shiraki, T; Uematsu, M; Watanabe, T | 1 |
Karnabatidis, D; Katsanos, K; Kitrou, PM; Siablis, D; Spiliopoulos, S | 1 |
Micari, A; Vadalà, G | 1 |
Ansel, GM; Dake, MD; Jaff, MR; Kichikawa, K; Kimura, T; O'Leary, EE; Ohki, T; Ragheb, AO; Snyder, SA; Yokoi, H | 1 |
Herten, M; Imm, B; Osada, N; Schönefeld, E; Stahlhoff, S; Torsello, GB | 1 |
Dattilo, R; Gongora, CA; Granada, JF; Hyon, CM; Kaluza, GL; Mustapha, JA; Palmieri, T; Rousselle, S; Tellez, A | 1 |
Fujihara, M; Higashimori, A; Nakamura, M; Utsunomiya, M; Yokoi, Y | 1 |
Chaillou, P; Costargent, A; Fairier, D; Gestin, S; Gouëffic, Y; Guyomarch, B; Kaladji, A; Montagne, C; Patra, P; Riche, VP; Vent, PA | 1 |
Burket, MW; Moukarbel, GV | 1 |
Lansky, AJ; Mena, C; Ng, VG; Pietras, C | 1 |
Albrecht, T; Brechtel, K; Claussen, CD; Scheller, B; Schnorr, B; Speck, U; Tepe, G; Zeller, T | 1 |
Jaff, MR | 1 |
Duda, S; Lux, B; Martorana, M; Meyer, DR; Ruecker, F; Schroeder, H | 1 |
Lammer, J; Scheinert, D; Schulte, KL; Tepe, G; Zeller, T | 1 |
Aihara, H; Ando, K; Kuramitsu, S; Nobuyoshi, M; Soga, Y; Tomoi, Y | 1 |
Airoldi, F; Cetta, F; Clerici, G; Losa, S; Oberto, S; Rossi, F; Spirito, R; Tavano, D; Trabattoni, P; Zoli, S | 1 |
Benenati, J; Jaff, MR; Nehler, M; Rocha-Singh, K; Rosenfield, K; Scheinert, D; White, CJ | 1 |
Hirano, K; Ishimori, H; Ito, Y; Mori, S; Muramatsu, T; Nakano, M; Tsukahara, R | 1 |
Armstrong, EJ; Foley, TR | 1 |
Morrow, T | 1 |
Donas, KP; Herten, M; Osada, N; Stahlhoff, S; Torsello, G | 1 |
Benenati, JF; Brodmann, M; Gammon, R; Jaff, MR; Krishnan, P; Mena-Hurtado, C; Metzger, DC; Müller-Hülsbeck, S; Nehler, MR; Pilger, E; Rocha-Singh, K; Rosenfield, K; Scheinert, D; White, CJ; Zeller, T | 1 |
Mayor, S | 1 |
Iida, O; Kawasaki, D; Nakano, M; Nanto, S; Soga, Y; Takahara, M; Uematsu, M; Yamauchi, Y; Yokoi, H; Zen, K | 1 |
Cheng, Y; Conditt, GB; Gongora, CA; Granada, JF; Kaluza, GL; McGregor, J; Shibuya, M; Tellez, A; Wessler, JD | 1 |
Hehrlein, C | 1 |
Anderson, J; Kelly, P; Lamichhane, S; Mani, G; Remund, T | 1 |
Fujii, K; Fukunaga, M; Horimatsu, T; Imanaka, T; Ishihara, M; Masuyama, T; Miki, K; Naito, Y; Nishimura, M; Saita, T; Shibuya, M; Sumiyoshi, A; Tamaru, H | 1 |
Chaillou, P; Costargent, A; Davaine, JM; Gouëffic, Y; Guyomarch, B; Kaladji, A; Querat, J; Quillard, T | 1 |
Aspalter, M; Hitzl, W; Hölzenbein, T; Linni, K; Ugurluoglu, A | 1 |
Tsai, TT | 1 |
Beschorner, U; Bosiers, M; Brodmann, M; Deloose, K; Peeters, P; Pilger, E; Rastan, A; Scheinert, D; Schulte, KL; Zeller, T | 1 |
Metzger, DC; Rosenfield, K; Scheinert, D | 1 |
Al-Omran, M; Hussain, MA | 1 |
El Batti, S; Mohammedi, K; Potier, L | 1 |
Banning-Eichenseer, U; Bausback, Y; Scheinert, D; Scheinert, S; Schmidt, A; Steiner, S; Ulrich, M; Werner, M | 1 |
Diamantopoulos, A; Karnabatidis, D; Katsanos, K; Paraskevopoulos, I; Spiliopoulos, S | 1 |
Dake, MD; Kichikawa, K; Komori, K; Lottes, AE; Nakamura, M; Nanto, S; O'Leary, EE; Ohki, T; Snyder, SA; Yokoi, H | 1 |
Dansey, K; Shames, M; Wooster, M | 1 |
Fitzgerald, PJ; Fujii, K; Fukunaga, M; Honda, Y; Horimatsu, T; Imanaka, T; Ishihara, M; Kawasaki, D; Kimura, T; Masuyama, T; Miki, K; Nishimura, M; Okada, K; Saita, T; Shibuya, M; Sumiyoshi, A; Tamaru, H | 1 |
Banning-Eichenseer, U; Bausback, Y; Bräunlich, S; Scheinert, D; Schmidt, A; Steiner, S; Ulrich, M | 1 |
Ketelsen, D; Müller-Hülsbeck, S; Ricke, J; Rosenfield, K; Scheinert, D; Schmidt, A; Schröder, H; Sixt, S; Steiner, S; Weiss, N; Zeller, T | 1 |
Karnabatidis, D; Katsanos, K; Kitrou, P | 1 |
Castriota, F; Cesana, BM; Cremonesi, A; Grattoni, C; Liso, A; Marchese, A; Micari, A; Pantaleo, P; Roscitano, G; Russo, P; Vadalà, G | 1 |
Lee, MS; Sethi, SS | 1 |
Funovics, M; Gschwandtner, M; Javor, D; Kinstner, CM; Koppensteiner, R; Lammer, J; Loewe, C; Matzek, W; Ristl, R; Schoder, M; Willfort-Ehringer, A; Wolf, F | 1 |
Al-Atassi, T; Kayssi, A; Oreopoulos, G; Rajan, DK; Roche-Nagle, G; Tan, KT | 1 |
Baker, NC; Bernardo, NL; Campia, U; Didier, RJ; Escarcega, RO; Kang, WY; Kiramijyan, S; Koifman, E; Lipinski, MJ; Negi, SI; Torguson, R; Waksman, R | 1 |
Du, X; Guo, W; Hu, ZZ; Jia, SH; Jia, X; Liu, XP; Sun, GY; Xu, YL; Zhang, J | 1 |
Ang, H; Chan, JN; Foin, N; Huang, Y; Lin, J; Lui, YS; Phua, JL; Venkatraman, S; Xiong, GM | 1 |
Hirano, K; Iida, O; Soga, Y; Takahara, M; Uematsu, M; Yamauchi, Y; Yokoi, H; Zen, K | 1 |
Herten, M; Schönefeld, E; Stahlhoff, S; Torsello, GB | 1 |
Bi, W; Fu, W; Guo, P; Guo, W; Jia, X; Wang, F; Wang, S; Wu, D; Zhang, J; Zhao, Y; Zhuang, B | 1 |
Aerden, D; Debing, E; Gallala, S; Vanhulle, A; von Kemp, K | 1 |
Del Giudice, C; Gandini, R | 1 |
Hawkins, BM | 1 |
Aschenbach, R; Blessing, E; Brechtel, K; Lehmann, T; Lichtenberg, M; Riambau, V; Scheinert, D; Sixt, S; Teichgräber, U; Thieme, M; Treitl, M; Vogel, B; von Flotow, P; Werk, M; Wienke, A; Zeller, T | 1 |
Beropoulis, E; Bisdas, T; Bosiers, MJ; Hericks, C; Schwindt, A; Stachmann, A; Stahlhoff, S; Stavroulakis, K; Torsello, G | 1 |
Farquharson, F; Lake, E; Twigg, M | 1 |
Iida, O; Kawasaki, D; Matoba, S; Nanto, S; Soga, Y; Takahara, M; Yokoi, H; Zen, K | 1 |
Akduman, EI; Altinbas, NK; Bilici, M; Oz, EB; Oz, II; Serifoglu, I | 1 |
Candy, N; Ng, E; Velu, R | 1 |
Mehrotra, S; Mishra, S; Paramasivam, G | 1 |
Chaillou, P; Costargent, A; Davaine, JM; Gouëffic, Y; Guyomarch, B; Kaladji, A; Quillard, T; Vent, PA | 1 |
Hawkins, BM; Hennebry, TA | 1 |
Ansel, GM; Burket, MW; Dake, MD; Jaff, MR; Khatib, Y; Machan, LS; Ohki, T; Ragheb, AO; Roubin, GS; Saxon, RR; Smouse, HB; Snyder, SA; White, JK; Zeller, T | 1 |
Albrecht, T; Schnorr, B | 1 |
Bosiers, M; Deloose, K; Peeters, P; Strickler, S; Tessarek, J | 1 |
55 review(s) available for paclitaxel and Peripheral Arterial Diseases
Article | Year |
---|---|
[Use of endovascular drug-coated devices in lesions of femoropopliteoltibial arteries].
Topics: Angioplasty, Balloon; Arteries; Cardiovascular Agents; Coated Materials, Biocompatible; Humans; Paclitaxel; Peripheral Arterial Disease; Pharmaceutical Preparations; Stents; Treatment Outcome; Vascular Patency | 2021 |
Vascular Quality Initiative Surveillance of Femoropopliteal Artery Paclitaxel Devices.
Topics: Angioplasty, Balloon; Cardiovascular Agents; Cohort Studies; Drug-Eluting Stents; Femoral Artery; Humans; Multicenter Studies as Topic; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Treatment Outcome; Vascular Patency | 2021 |
Endovascular treatment of high-risk peripheral vascular occlusive lesions: a review of current evidence and emerging applications of intravascular lithotripsy, atherectomy, and paclitaxel-coated devices.
Topics: Angioplasty, Balloon; Atherectomy; Femoral Artery; Humans; Lithotripsy; Paclitaxel; Peripheral Arterial Disease; Treatment Outcome; Vascular Patency | 2021 |
Re: "Risk of Major Amputation Following Application of Paclitaxel Coated Balloons in the Lower Limb Arteries: A Systematic Review and Meta-analysis of Randomised Controlled Trials".
Topics: Amputation, Surgical; Angioplasty, Balloon; Arteries; Cardiovascular Agents; Coated Materials, Biocompatible; Humans; Lower Extremity; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Randomized Controlled Trials as Topic; Treatment Outcome | 2022 |
Network Analysis of Endovascular Treatment Strategies for Femoropopliteal Arterial Occlusive Disease.
Topics: Arterial Occlusive Diseases; Bayes Theorem; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Sirolimus; Stents; Treatment Outcome; Vascular Patency | 2023 |
Systematic Review and Meta-analysis of the Outcomes of Drug-Eluting Stent Versus Drug-Coated Balloon Angioplasty for Lower Extremity Peripheral Artery Diseases.
Topics: Angioplasty, Balloon; Coated Materials, Biocompatible; Drug-Eluting Stents; Femoral Artery; Humans; Lower Extremity; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Randomized Controlled Trials as Topic; Treatment Outcome | 2022 |
The Use of Paclitaxel-Coated Devices in the Treatment of Peripheral Arterial Disease is Not Associated With Increased Mortality or Amputations.
Topics: Angioplasty, Balloon; Coated Materials, Biocompatible; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Treatment Outcome; Vascular Patency | 2022 |
Safety and Efficacy of Drug-Coated Balloon in the Treatment of Below-the-Knee Artery: A Meta-analysis.
Topics: Angioplasty, Balloon; Coated Materials, Biocompatible; Femoral Artery; Follow-Up Studies; Humans; Ischemia; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; Vascular Patency | 2022 |
Safety of paclitaxel-coated devices in the femoropopliteal arteries: A systematic review and meta-analysis.
Topics: Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Drug-Eluting Stents; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Risk Factors; Treatment Outcome | 2022 |
The Current Use of Drug-Eluting Balloons and Stents in Peripheral Arterial Disease: An Online Survey by the Cardiovascular and Interventional Radiological Society of Europe (CIRSE).
Topics: Angioplasty, Balloon; Coated Materials, Biocompatible; Drug-Eluting Stents; Europe; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Stents; Treatment Outcome | 2023 |
[Angioplasty with Sirolimus-coated Balloon: the New Standard in the Treatment of PAD?]
Topics: Angioplasty; Angioplasty, Balloon; Coated Materials, Biocompatible; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Sirolimus; Treatment Outcome | 2023 |
Mortality in randomised controlled trials using paclitaxel-coated devices for femoropopliteal interventional procedures: an updated patient-level meta-analysis.
Topics: Boston; Cardiovascular Agents; Coated Materials, Biocompatible; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome | 2023 |
Is There a Safety Concern for Drug-Coated Balloons in Peripheral Arterial Disease?
Topics: Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Drug-Eluting Stents; Endovascular Procedures; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prosthesis Design; Treatment Outcome | 2019 |
Mortality Assessment of Paclitaxel-Coated Balloons: Patient-Level Meta-Analysis of the ILLUMENATE Clinical Program at 3 Years.
Topics: Aged; Angioplasty; Drug-Eluting Stents; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Proportional Hazards Models; Randomized Controlled Trials as Topic | 2019 |
Bayes Factor Meta-Analysis of the Mortality Claim for Peripheral Paclitaxel-Eluting Devices.
Topics: Angioplasty, Balloon; Bayes Theorem; Cardiovascular Agents; Coated Materials, Biocompatible; Drug-Eluting Stents; Humans; Paclitaxel; Peripheral Arterial Disease; Prosthesis Design; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Vascular Access Devices | 2019 |
Editor's Choice - Drug Coated Balloon Angioplasty vs. Standard Percutaneous Transluminal Angioplasty in Below the Knee Peripheral Arterial Disease: A Systematic Review and Meta-Analysis.
Topics: Amputation, Surgical; Angioplasty, Balloon; Coated Materials, Biocompatible; Drug-Eluting Stents; Femoral Artery; Humans; Limb Salvage; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Survival Analysis; Treatment Outcome; Vascular Patency | 2020 |
Paclitaxel-related balloons and stents for the treatment of peripheral artery disease: Insights from the Food and Drug Administration 2019 Circulatory System Devices Panel Meeting on late mortality.
Topics: Angioplasty, Balloon; Antineoplastic Agents, Phytogenic; Coated Materials, Biocompatible; Congresses as Topic; Humans; Paclitaxel; Peripheral Arterial Disease; Prosthesis Design; Stents; United States; United States Food and Drug Administration | 2020 |
Mortality After Paclitaxel-Coated Device Use in Patients With Chronic Limb-Threatening Ischemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Topics: Aged; Angioplasty, Balloon; Cardiovascular Agents; Cause of Death; Chronic Disease; Coated Materials, Biocompatible; Drug-Eluting Stents; Female; Humans; Ischemia; Male; Paclitaxel; Peripheral Arterial Disease; Prosthesis Design; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Vascular Access Devices | 2020 |
Balloon catheters and stents with paclitaxel: are they really dangerous? A review and update.
Topics: Cardiovascular Agents; Coated Materials, Biocompatible; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Retrospective Studies; Stents; Treatment Outcome; Urinary Catheters; Vascular Patency | 2021 |
Mortality and Paclitaxel-Coated Devices: An Individual Patient Data Meta-Analysis.
Topics: Angioplasty, Balloon; Data Analysis; Drug-Eluting Stents; Humans; Mortality; Paclitaxel; Peripheral Arterial Disease; Randomized Controlled Trials as Topic | 2020 |
Zilver PTX peripheral paclitaxel-eluting stent: a technology evaluation.
Topics: Drug-Eluting Stents; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Technology; Treatment Outcome | 2020 |
Mortality in patients undergoing revascularization with paclitaxel eluting devices for infrainguinal peripheral artery disease: Insights from a network meta-analysis of randomized trials.
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Agents; Coated Materials, Biocompatible; Drug-Eluting Stents; Endovascular Procedures; Female; Humans; Male; Middle Aged; Network Meta-Analysis; Paclitaxel; Peripheral Arterial Disease; Prosthesis Design; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Vascular Access Devices | 2020 |
Important considerations for trials for peripheral arterial disease: Lessons learned from the paclitaxel mortality signal: A report on behalf of the registry assessment for peripheral interventional Devices (RAPID) Paclitaxel Pathways Program.
Topics: Advisory Committees; Angioplasty; Angioplasty, Balloon; Atherectomy; Common Data Elements; Data Accuracy; Data Collection; Drug-Eluting Stents; Femoral Artery; Humans; Meta-Analysis as Topic; Mortality; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Randomized Controlled Trials as Topic; Reproducibility of Results; Risk Assessment; Stents; Tubulin Modulators | 2021 |
The Safety of Paclitaxel-Coated Devices for Patients with Peripheral Artery Disease.
Topics: Angioplasty, Balloon; Coated Materials, Biocompatible; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Treatment Outcome; Vascular Patency | 2021 |
The Rollercoaster of Paclitaxel in the Lower Limbs and Skeletons in the Closet: An Opinion Review.
Topics: Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Drug-Eluting Stents; Evidence-Based Medicine; Humans; Lower Extremity; Paclitaxel; Patient Safety; Peripheral Arterial Disease; Prosthesis Design; Risk Assessment; Risk Factors; Treatment Outcome; Vascular Access Devices | 2021 |
An Individual-Level Meta-Analysis Using Real-World and Pivotal Studies on Mortality From the Use of Paclitaxel-Containing Devices in Japanese Femoropopliteal Disease Patients.
Topics: Aged; Angioplasty, Balloon; Diabetes Mellitus, Type 2; Femoral Artery; Humans; Japan; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Treatment Outcome; Vascular Patency | 2021 |
Mortality Rates After Paclitaxel-Coated Device Use in Patients With Occlusive Femoropopliteal Disease: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Topics: Coated Materials, Biocompatible; Humans; Paclitaxel; Peripheral Arterial Disease; Randomized Controlled Trials as Topic; Treatment Outcome | 2021 |
Editor's Choice - Risk of Major Amputation Following Application of Paclitaxel Coated Balloons in the Lower Limb Arteries: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.
Topics: Amputation, Surgical; Angioplasty, Balloon; Femoral Artery; Humans; Lower Extremity; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Randomized Controlled Trials as Topic; Risk Factors | 2022 |
Peripheral artery disease: Drug-coated balloon superior to standard balloon angioplasty.
Topics: Angioplasty, Balloon; Antineoplastic Agents, Phytogenic; Coated Materials, Biocompatible; Equipment Design; Humans; Paclitaxel; Peripheral Arterial Disease; Treatment Outcome | 2017 |
New Innovations in Drug-Eluting Stents for Peripheral Arterial Disease.
Topics: Absorbable Implants; Blood Vessel Prosthesis Implantation; Drug-Eluting Stents; Endovascular Procedures; Humans; Paclitaxel; Peripheral Arterial Disease; Therapies, Investigational; Tubulin Modulators | 2017 |
Critical limb ischemia update and the evolving role of drug-elution technologies.
Topics: Angioplasty, Balloon; Cardiovascular Agents; Drug-Eluting Stents; Humans; Lower Extremity; Paclitaxel; Peripheral Arterial Disease; Treatment Outcome | 2017 |
Drug-eluting stents for the treatment of complex femoro-popliteal disease: a systematic review and meta-analysis.
Topics: Drug-Eluting Stents; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prosthesis Design; Treatment Outcome; Vascular Patency | 2022 |
Paclitaxel density and clinical efficacy of drug-coated balloon angioplasty for femoropopliteal artery disease: meta-analysis and adjusted indirect comparison of 20 randomised trials.
Topics: Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Coated Materials, Biocompatible; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Randomized Controlled Trials as Topic; Treatment Outcome; Vascular Patency | 2019 |
Risk of Death Following Application of Paclitaxel-Coated Balloons and Stents in the Femoropopliteal Artery of the Leg: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Topics: Aged; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Drug-Eluting Stents; Female; Femoral Artery; Humans; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prosthesis Design; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Vascular Access Devices | 2018 |
Directional atherectomy with antirestenotic therapy for the treatment of no-stenting zones.
Topics: Angioplasty, Balloon; Atherectomy; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Humans; Paclitaxel; Peripheral Arterial Disease; Recurrence; Risk Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2019 |
Mortality Not Correlated With Paclitaxel Exposure: An Independent Patient-Level Meta-Analysis of a Drug-Coated Balloon.
Topics: Angioplasty, Balloon; Antineoplastic Agents, Phytogenic; Coated Materials, Biocompatible; Endovascular Procedures; Femoral Artery; Global Health; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Survival Rate | 2019 |
Association of Survival With Femoropopliteal Artery Revascularization With Drug-Coated Devices.
Topics: Aged; Aged, 80 and over; Angioplasty; Drug-Eluting Stents; Extremities; Female; Femoral Artery; Humans; Male; Medicare; Middle Aged; Mortality; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome; Tubulin Modulators; United States | 2019 |
Paclitaxel-Based Therapies for Patients With Peripheral Artery Disease.
Topics: Humans; Paclitaxel; Peripheral Arterial Disease | 2019 |
Drug-eluting stents for PAD: what does (all) the data tell us?
Topics: Angioplasty, Balloon; Device Approval; Drug-Eluting Stents; Humans; Paclitaxel; Peripheral Arterial Disease; Prosthesis Design; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration | 2019 |
Current concepts regarding drug dosing for peripheral stents.
Topics: Drug Delivery Systems; Drug-Eluting Stents; Everolimus; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Polymers; Secondary Prevention; Sirolimus; Stents; TOR Serine-Threonine Kinases | 2019 |
Critical review and evidence implications of paclitaxel drug-eluting balloons and stents in peripheral artery disease.
Topics: Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Drug-Eluting Stents; Evidence-Based Medicine; Humans; Paclitaxel; Patient Safety; Peripheral Arterial Disease; Prosthesis Design; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Vascular Access Devices | 2019 |
Bayesian network meta-analysis of nitinol stents, covered stents, drug-eluting stents, and drug-coated balloons in the femoropopliteal artery.
Topics: Alloys; Amputation, Surgical; Angioplasty, Balloon; Bayes Theorem; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Drug-Eluting Stents; Equipment Design; Femoral Artery; Humans; Limb Salvage; Odds Ratio; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prosthesis Design; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Sirolimus; Stents; Treatment Outcome; Vascular Access Devices | 2014 |
Paclitaxel-eluting stents for the treatment of femoropopliteal arterial stenoses: focus on the Zilver PTX drug-eluting peripheral stent.
Topics: Clinical Trials as Topic; Constriction, Pathologic; Drug-Eluting Stents; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery | 2015 |
Local delivery of paclitaxel in the treatment of peripheral arterial disease.
Topics: Angioplasty, Balloon; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug-Eluting Stents; Glycerol; Humans; Infusions, Intravenous; Iohexol; Nanoparticles; Paclitaxel; Peripheral Arterial Disease; Pharmaceutical Vehicles; Tubulin Modulators | 2015 |
Paclitaxel Drug-Eluting Stents in Peripheral Arterial Disease: A Health Technology Assessment.
Topics: Antineoplastic Agents, Phytogenic; Cost-Benefit Analysis; Drug-Eluting Stents; Humans; Paclitaxel; Peripheral Arterial Disease; Technology Assessment, Biomedical | 2015 |
Systematic Review and Meta-analysis of Randomized Controlled Trials of Paclitaxel-Coated Balloon Angioplasty in the Femoropopliteal Arteries: Role of Paclitaxel Dose and Bioavailability.
Topics: Amputation, Surgical; Angioplasty, Balloon; Biological Availability; Cardiovascular Agents; Chi-Square Distribution; Coated Materials, Biocompatible; Constriction, Pathologic; Equipment Design; Femoral Artery; Humans; Limb Salvage; Odds Ratio; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2016 |
Drug-coated balloons are replacing the need for nitinol stents in the superficial femoral artery.
Topics: Alloys; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Cost-Benefit Analysis; Female; Femoral Artery; Health Care Costs; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Prosthesis Design; Stents; Treatment Outcome; Vascular Access Devices | 2016 |
Drug-Coated Balloons for Infrainguinal Peripheral Artery Disease.
Topics: Angioplasty; Antineoplastic Agents, Phytogenic; Coated Materials, Biocompatible; Constriction, Pathologic; Drug-Eluting Stents; Femoral Artery; Humans; Hyperplasia; Long Term Adverse Effects; Neointima; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Vascular Patency | 2016 |
Drug-eluting balloon angioplasty versus uncoated balloon angioplasty for peripheral arterial disease of the lower limbs.
Topics: Amputation, Surgical; Angioplasty, Balloon; Drug-Eluting Stents; Femoral Artery; Humans; Lower Extremity; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Randomized Controlled Trials as Topic; Tibial Arteries; Time Factors; Vascular Patency | 2016 |
Materials technology in drug eluting balloons: Current and future perspectives.
Topics: Animals; Clinical Trials as Topic; Drug Delivery Systems; Drug-Eluting Stents; Humans; Materials Testing; Nanostructures; Paclitaxel; Peripheral Arterial Disease; Prosthesis Design | 2016 |
Critical appraisal of paclitaxel balloon angioplasty for femoral-popliteal arterial disease.
Topics: Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Critical Illness; Equipment Design; Femoral Artery; Humans; Ischemia; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2016 |
Paclitaxel-coated balloon reduces target lesion revascularization compared with standard balloon angioplasty.
Topics: Amputation, Surgical; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Equipment Design; Humans; Limb Salvage; Odds Ratio; Paclitaxel; Peripheral Arterial Disease; Retreatment; Risk Factors; Treatment Outcome; Vascular Access Devices | 2017 |
Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease.
Topics: Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Drug-Eluting Stents; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Randomized Controlled Trials as Topic; Treatment Outcome; Vascular Patency | 2017 |
Local paclitaxel delivery for treatment of peripheral arterial disease.
Topics: Cerebrovascular Disorders; Drug Delivery Systems; Drug-Eluting Stents; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Renal Artery Obstruction | 2011 |
Drug-coated balloons and their place in treating peripheral arterial disease.
Topics: Angioplasty, Balloon; Catheterization, Peripheral; Drug-Eluting Stents; Equipment Failure Analysis; Humans; Paclitaxel; Peripheral Arterial Disease; Prosthesis Design; Tubulin Modulators | 2013 |
92 trial(s) available for paclitaxel and Peripheral Arterial Diseases
Article | Year |
---|---|
One-year results for Japanese patients in RANGER II SFA.
Topics: Angioplasty, Balloon; Coated Materials, Biocompatible; Femoral Artery; Humans; Japan; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Time Factors; Treatment Outcome; Vascular Patency | 2022 |
Head-to-head comparison of sirolimus- versus paclitaxel-coated balloon angioplasty in the femoropopliteal artery: study protocol for the randomized controlled SIRONA trial.
Topics: Angioplasty, Balloon; Coated Materials, Biocompatible; Femoral Artery; Humans; Multicenter Studies as Topic; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Quality of Life; Randomized Controlled Trials as Topic; Sirolimus; Treatment Outcome; Vascular Patency | 2021 |
Paclitaxel-coated balloons versus percutaneous transluminal angioplasty for infrapopliteal chronic total occlusions: the IN.PACT BTK randomised trial.
Topics: Angioplasty; Angioplasty, Balloon; Coated Materials, Biocompatible; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Pilot Projects; Popliteal Artery; Prospective Studies; Time Factors; Treatment Outcome; Vascular Patency | 2022 |
Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery Revascularization: Insights From VOYAGER PAD.
Topics: Antineoplastic Agents, Phytogenic; Cardiovascular Diseases; Chronic Limb-Threatening Ischemia; Drug-Eluting Stents; Endovascular Procedures; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Outcome Assessment, Health Care; Paclitaxel; Peripheral Arterial Disease; Postoperative Complications; Proportional Hazards Models | 2021 |
No Mortality Signal With Stellarex Low-Dose Paclitaxel DCB: ILLUMENATE Pivotal 4-Year Outcomes.
Topics: Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Time Factors; Treatment Outcome; Vascular Patency | 2022 |
Assessment of Sirolimus- vs. paCLitaxEl-coated balloon angioPlasty In atherosclerotic femoropopliteal lesiOnS (ASCLEPIOS Study): preliminary results.
Topics: Aged; Amputation, Surgical; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Female; Femoral Artery; Humans; Limb Salvage; Male; Paclitaxel; Peripheral Arterial Disease; Plaque, Atherosclerotic; Popliteal Artery; Progression-Free Survival; Sirolimus; Time Factors; Vascular Patency | 2022 |
Drug-Eluting Balloon for Below the Knee Angioplasty: Five-Year Outcome of the DEBATE-BTK Randomized Clinical Trial.
Topics: Angioplasty, Balloon; Coated Materials, Biocompatible; Cohort Studies; Drug-Eluting Stents; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Treatment Outcome | 2022 |
Major adverse limb events in patients with femoro-popliteal and below-the-knee peripheral arterial disease treated with either sirolimus-coated balloon or standard uncoated balloon angioplasty: a structured protocol summary of the "SirPAD" randomized cont
Topics: Angioplasty, Balloon; Clinical Trials, Phase III as Topic; Coated Materials, Biocompatible; Constriction, Pathologic; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Randomized Controlled Trials as Topic; Sirolimus; Treatment Outcome; Vascular Patency | 2022 |
IN.PACT AV Access Trial: Economic Evaluation of Drug-Coated Balloon Treatment for Dysfunctional Arteriovenous Fistulae Based on 12-Month Clinical Outcomes.
Topics: Aged; Angioplasty, Balloon; Arteriovenous Fistula; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Cost-Benefit Analysis; Femoral Artery; Humans; Medicare; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Time Factors; Treatment Outcome; United States; Vascular Patency | 2022 |
Sirolimus-Coated Balloon Angioplasty of Infra-popliteal Lesions for the Treatment of Chronic Limb-Threatening Ischemia: Study Protocol for the Randomized Controlled LIMES Study.
Topics: Angioplasty, Balloon; Chronic Limb-Threatening Ischemia; Citrus aurantiifolia; Coated Materials, Biocompatible; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Sirolimus; Treatment Outcome; Vascular Patency | 2022 |
Jetstream Atherectomy Followed by Paclitaxel-Coated Balloons versus Balloon Angioplasty Followed by Paclitaxel-Coated Balloons: Twelve-Month Exploratory Results of the Prospective Randomized JET-RANGER Study.
Topics: Angioplasty, Balloon; Atherectomy; Coated Materials, Biocompatible; COVID-19; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Time Factors; Treatment Outcome; Vascular Patency | 2022 |
The RANGER II superficial femoral artery trial: 1-year results of the long lesion cohort.
Topics: Angioplasty, Balloon; Calcium; Coated Materials, Biocompatible; Cohort Studies; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Time Factors; Treatment Outcome; Vascular Patency | 2022 |
One-Year Results of Long femoropopliteal Lesions Stenting with Fasciotomy Lamina Vastoadductoria.
Topics: Constriction, Pathologic; Fasciotomy; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prosthesis Design; Stents; Treatment Outcome; Vascular Patency | 2023 |
Methodology of the BIOPACT RCT, a Multi-center, Randomized, Non-inferiority Trial Evaluating Safety and Efficacy of Passeo-18 Lux Drug-Coated Balloon (DCB) of Biotronik Compared to the Medtronic IN.PACT Admiral DCB in the Treatment of Subjects with Lesion
Topics: Angioplasty, Balloon; Coated Materials, Biocompatible; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Time Factors; Treatment Outcome; Vascular Patency | 2022 |
Low-Dose vs High-Dose Paclitaxel-Coated Balloons for Femoropopliteal Lesions: 2-Year Results From the COMPARE Trial.
Topics: Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Pilot Projects; Polychlorinated Biphenyls; Popliteal Artery; Prospective Studies; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2022 |
Twelve-Month Outcomes of a Novel Iopromide-Based Paclitaxel-Coated Balloon for the Treatment of Chronic Total Occlusion of Femoropopliteal Arteries.
Topics: Angioplasty, Balloon; Cardiovascular Agents; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Retrospective Studies; Treatment Outcome | 2023 |
Jetstream Atherectomy with Paclitaxel-Coated Balloons: Two-Year Outcome of the Prospective Randomized JET-RANGER Study.
Topics: Angioplasty, Balloon; Atherectomy; Carcinoma, Renal Cell; Femoral Artery; Humans; Kidney Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Time Factors; Treatment Outcome; Vascular Patency | 2023 |
ZILVERPASS Study: ZILVER PTX Stent vs. Bypass Surgery in Femoropopliteal Lesions, 3 year results and economic analysis.
Topics: Aged; Drug-Eluting Stents; Femoral Artery; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Stents; Treatment Outcome; Vascular Patency | 2023 |
ZILVERPASS Study: ZILVER PTX Stent versus Prosthetic Above-the-Knee Bypass Surgery in Femoropopliteal Lesions, 5-year Results.
Topics: Aged; Drug-Eluting Stents; Femoral Artery; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Prosthesis Design; Stents; Treatment Outcome; Vascular Patency | 2023 |
Primary results of the SAVAL randomized trial of a paclitaxel-eluting nitinol stent versus percutaneous transluminal angioplasty in infrapopliteal arteries.
Topics: Angioplasty; Angioplasty, Balloon; Drug-Eluting Stents; Humans; Ischemia; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Stents; Treatment Outcome; Vascular Patency | 2023 |
Drug-coated balloon for treatment of non-atherosclerotic renal artery stenosis-a multi-center study.
Topics: Angioplasty, Balloon; Coated Materials, Biocompatible; Femoral Artery; Humans; Multicenter Studies as Topic; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Randomized Controlled Trials as Topic; Renal Artery Obstruction; Time Factors; Treatment Outcome; Vascular Patency | 2023 |
Drug-Coated Balloon Angioplasty in Clinical Practice for Below-the-Knee, Popliteal, and Crural Artery Lesions Causing Critical Limb Ischemia: 1-Year Results from the Spanish Luminor Registry.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Critical Illness; Equipment Design; Female; Femoral Artery; Humans; Ischemia; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Progression-Free Survival; Prospective Studies; Risk Factors; Spain; Time Factors; Vascular Access Devices; Vascular Patency | 2020 |
Paclitaxel-Coated Zilver PTX Drug-Eluting Stent Treatment Does Not Result in Increased Long-Term All-Cause Mortality Compared to Uncoated Devices.
Topics: Aged; Angioplasty; Drug-Eluting Stents; Female; Femoral Artery; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Stents; Treatment Outcome; Tubulin Modulators; Vascular Patency | 2020 |
Efficacy and safety of a novel paclitaxel-nano-coated balloon for femoropopliteal angioplasty: one-year results of the EffPac trial.
Topics: Angioplasty; Angioplasty, Balloon; Coated Materials, Biocompatible; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Time Factors; Treatment Outcome; Vascular Access Devices | 2020 |
Cost-Effectiveness of Drug-Eluting Stents for Infrapopliteal Lesions in Patients with Critical Limb Ischemia: The PADI Trial.
Topics: Adult; Amputation, Surgical; Angioplasty; Cost-Benefit Analysis; Disease-Free Survival; Drug-Eluting Stents; Female; Humans; Ischemia; Male; Netherlands; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Treatment Outcome; Vascular Patency | 2020 |
COMPARE: prospective, randomized, non-inferiority trial of high- vs. low-dose paclitaxel drug-coated balloons for femoropopliteal interventions.
Topics: Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Pharmaceutical Preparations; Popliteal Artery; Prospective Studies; Time Factors; Treatment Outcome; Vascular Patency | 2020 |
Effectiveness and Safety of a Paclitaxel-Eluting Stent for Superficial Femoral Artery Lesions up to 190 mm: One-Year Outcomes of the Single-Arm IMPERIAL Long Lesion Substudy of the Eluvia Drug-Eluting Stent.
Topics: Aged; Amputation, Surgical; Cardiovascular Agents; Constriction, Pathologic; Drug-Eluting Stents; Endovascular Procedures; Europe; Female; Femoral Artery; Humans; Japan; Limb Salvage; Male; Middle Aged; New Zealand; Paclitaxel; Patient Safety; Peripheral Arterial Disease; Progression-Free Survival; Prospective Studies; Prosthesis Design; Risk Assessment; Risk Factors; Time Factors; United States; Vascular Calcification; Vascular Patency | 2020 |
ZILVERPASS Study: ZILVER PTX Stent vs Bypass Surgery in Femoropopliteal Lesions.
Topics: Aged; Aged, 80 and over; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Brazil; Cardiovascular Agents; Drug-Eluting Stents; Endovascular Procedures; Europe; Female; Femoral Artery; Humans; Length of Stay; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Prosthesis Design; Recurrence; Risk Factors; Time Factors; Treatment Outcome; Vascular Patency | 2020 |
One-year results of drug-coated balloons for long and occlusive Femoropopliteal artery disease: a single-arm trial.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Beijing; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Female; Femoral Artery; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Retrospective Studies; Time Factors; Treatment Outcome; Vascular Patency | 2020 |
The IN.PACT DEEP Clinical Drug-Coated Balloon Trial: 5-Year Outcomes.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Critical Illness; Equipment Design; Europe; Female; Humans; Ischemia; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Prospective Studies; Recurrence; Risk Factors; Time Factors; Treatment Outcome; Vascular Patency | 2020 |
A Polymer-Free Paclitaxel-Eluting Stent Versus a Bare-Metal Stent for De Novo Femoropopliteal Lesions: The BATTLE Trial.
Topics: Aged; Aged, 80 and over; Cardiovascular Agents; Drug-Eluting Stents; Endovascular Procedures; Female; Femoral Artery; France; Humans; Male; Metals; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Prosthesis Design; Recurrence; Risk Factors; Stents; Time Factors; Treatment Outcome; Vascular Patency | 2020 |
Vascular Response After FP-PES Versus Polymer-Free Paclitaxel-Eluting Stent Implantation in Femoropopliteal Artery Lesions: A Serial Intravascular Ultrasound Study.
Topics: Cardiovascular Agents; Coronary Stenosis; Drug-Eluting Stents; Endovascular Procedures; Femoral Artery; Humans; Japan; Neointima; Paclitaxel; Peripheral Arterial Disease; Polymers; Popliteal Artery; Predictive Value of Tests; Prospective Studies; Risk Factors; Time Factors; Treatment Outcome; Ultrasonography, Interventional; Vascular Patency | 2020 |
Drug-coated Balloon Angioplasty of Femoropopliteal Lesions Maintained Superior Efficacy over Conventional Balloon: 2-year Results of the Randomized EffPac Trial.
Topics: Aged; Angioplasty, Balloon; Coated Materials, Biocompatible; Female; Femoral Artery; Germany; Humans; Lower Extremity; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Quality of Life; Single-Blind Method; Vascular Patency | 2020 |
Total IN.PACT All-Subjects One-Year Analysis and Standard vs Broader Implications.
Topics: Angioplasty, Balloon; Coated Materials, Biocompatible; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Time Factors; Treatment Outcome; Vascular Patency | 2020 |
Three-Year Results of the IN.PACT SFA Japan Trial Comparing Drug-Coated Balloons With Percutaneous Transluminal Angioplasty.
Topics: Aged; Aged, 80 and over; Angioplasty; Angioplasty, Balloon; Coated Materials, Biocompatible; Female; Femoral Artery; Humans; Japan; Male; Paclitaxel; Peripheral Arterial Disease; Pharmaceutical Preparations; Popliteal Artery; Prospective Studies; Time Factors; Treatment Outcome; Vascular Patency | 2020 |
Randomized Controlled Trial of Acotec Drug-Eluting Balloon Versus Plain Balloon for Below-the-Knee Angioplasty.
Topics: Angioplasty, Balloon; Coated Materials, Biocompatible; Drug-Eluting Stents; Humans; Paclitaxel; Peripheral Arterial Disease; Pharmaceutical Preparations; Popliteal Artery; Treatment Outcome | 2020 |
Reewarm™ PTX drug-coated balloon in the treatment of femoropopliteal artery disease: A multi-center, randomized controlled trial in China.
Topics: Aged; Angioplasty, Balloon; China; Coated Materials, Biocompatible; Femoral Artery; Humans; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Pharmaceutical Preparations; Popliteal Artery; Prospective Studies; Time Factors; Treatment Outcome | 2021 |
Two-Year Efficacy and Safety Results from the IMPERIAL Randomized Study of the Eluvia Polymer-Coated Drug-Eluting Stent and the Zilver PTX Polymer-free Drug-Coated Stent.
Topics: Aged; Drug-Eluting Stents; Endovascular Procedures; Female; Femoral Artery; Follow-Up Studies; Humans; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Treatment Outcome; Vascular Patency | 2021 |
Mortality with Paclitaxel-Coated Devices in Peripheral Artery Disease.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Ischemia; Male; Paclitaxel; Peripheral Arterial Disease; Proportional Hazards Models; Stents | 2020 |
Long-term safety and efficacy of angioplasty of femoropopliteal artery disease with drug-coated balloons from the AcoArt I trial.
Topics: Aged; Amputation, Surgical; Angioplasty, Balloon; Cardiovascular Agents; China; Coated Materials, Biocompatible; Equipment Design; Female; Femoral Artery; Humans; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Time Factors; Treatment Outcome; Vascular Access Devices | 2021 |
Microcrystalline paclitaxel-coated balloon for revascularization of femoropopliteal artery disease: Three-year outcomes of the randomized BIOPAC trial.
Topics: Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Treatment Outcome; Vascular Patency | 2021 |
Association between post-balloon angioplasty dissection and primary patency in complex femoropopliteal artery disease: 2-year clinical outcomes of the AcoArt I trial.
Topics: Angioplasty, Balloon; Coated Materials, Biocompatible; Dissection; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Time Factors; Treatment Outcome | 2021 |
1-Year Results From the RANGER II SFA Randomized Trial of the Ranger Drug-Coated Balloon.
Topics: Angioplasty, Balloon; Coated Materials, Biocompatible; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Pharmaceutical Preparations; Popliteal Artery; Prospective Studies; Time Factors; Treatment Outcome; Vascular Patency | 2021 |
Randomized Controlled Trial Comparing Drug-coated Balloon Angioplasty versus Conventional Balloon Angioplasty for Treating Below-the-Knee Arteries in Critical Limb Ischemia: The SINGA-PACLI Trial.
Topics: Angiography; Angioplasty, Balloon; Contrast Media; Double-Blind Method; Drug Delivery Systems; Female; Humans; Iohexol; Ischemia; Limb Salvage; Lower Extremity; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Prospective Studies; Tubulin Modulators | 2021 |
24-Month Efficacy and Safety Results from Japanese Patients in the IMPERIAL Randomized Study of the Eluvia Drug-Eluting Stent and the Zilver PTX Drug-Coated Stent.
Topics: Aged; Aged, 80 and over; Drug-Eluting Stents; Female; Femoral Artery; Humans; Japan; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Treatment Outcome; Vascular Patency | 2021 |
One-Year Outcomes of the Paclitaxel-Eluting, Self-Expanding Stentys Stent System in the Treatment of Infrapopliteal Lesions in Patients With Critical Limb Ischemia.
Topics: Aged; Aged, 80 and over; Alloys; Angiography; Belgium; Cardiovascular Agents; Constriction, Pathologic; Critical Illness; Drug-Eluting Stents; Endovascular Procedures; Female; Humans; Ischemia; Kaplan-Meier Estimate; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Prosthesis Design; Risk Factors; Self Expandable Metallic Stents; Time Factors; Treatment Outcome; Vascular Patency | 2017 |
Long-Term Follow-up of the PADI Trial: Percutaneous Transluminal Angioplasty Versus Drug-Eluting Stents for Infrapopliteal Lesions in Critical Limb Ischemia.
Topics: Amputation, Surgical; Angioplasty, Balloon; Cardiovascular Agents; Critical Illness; Disease-Free Survival; Drug-Eluting Stents; Humans; Ischemia; Kaplan-Meier Estimate; Limb Salvage; Lower Extremity; Netherlands; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prosthesis Design; Recurrence; Risk Factors; Time Factors; Treatment Outcome; Vascular Patency | 2017 |
Randomized Comparison of Paclitaxel-Eluting Balloon and Stenting Versus Plain Balloon Plus Stenting Versus Directional Atherectomy for Femoral Artery Disease (ISAR-STATH).
Topics: Aged; Angioplasty, Balloon; Atherectomy; Drug-Eluting Stents; Female; Femoral Artery; Follow-Up Studies; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease | 2017 |
Low-Dose Paclitaxel-Coated Versus Uncoated Percutaneous Transluminal Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease: One-Year Results of the ILLUMENATE European Randomized Clinical Trial (Randomized Trial of a Novel Paclitaxel-Coated Pe
Topics: Aged; Angioplasty; Angioplasty, Balloon; Coated Materials, Biocompatible; Europe; Female; Femoral Artery; Follow-Up Studies; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Single-Blind Method; Time Factors; Treatment Outcome | 2017 |
Six-Month Results From the Initial Randomized Study of the Ranger Paclitaxel-Coated Balloon in the Femoropopliteal Segment.
Topics: Aged; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Equipment Design; Europe; Female; Femoral Artery; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Recurrence; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2017 |
Angiographic and Clinical Outcomes After Treatment of Femoro-Popliteal Lesions with a Novel Paclitaxel-Matrix-Coated Balloon Catheter.
Topics: Aged; Angiography; Angioplasty, Balloon; Female; Femoral Artery; Germany; Humans; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Time Factors; Treatment Outcome; Tubulin Modulators | 2017 |
Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal Disease: Twelve-Month Outcomes From the Randomized ILLUMENATE Pivotal and Pharmacokinetic Studies.
Topics: Aged; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Female; Femoral Artery; Half-Life; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Prospective Studies; Severity of Illness Index; Single-Blind Method; Time Factors; Treatment Outcome; Vascular Patency | 2017 |
ISAR-PEBIS (Paclitaxel-Eluting Balloon Versus Conventional Balloon Angioplasty for In-Stent Restenosis of Superficial Femoral Artery): A Randomized Trial.
Topics: Aged; Aged, 80 and over; Angiography; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Disease-Free Survival; Endovascular Procedures; Equipment Design; Female; Femoral Artery; Germany; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Recurrence; Stents; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2017 |
Short-term Results of the RAPID Randomized Trial of the Legflow Paclitaxel-Eluting Balloon With Supera Stenting vs Supera Stenting Alone for the Treatment of Intermediate and Long Superficial Femoral Artery Lesions.
Topics: Aged; Alloys; Angiography; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Equipment Design; Female; Femoral Artery; Germany; Humans; Male; Middle Aged; Netherlands; Paclitaxel; Peripheral Arterial Disease; Prospective Studies; Self Expandable Metallic Stents; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Duplex; Vascular Access Devices; Vascular Patency | 2017 |
Directional Atherectomy Followed by a Paclitaxel-Coated Balloon to Inhibit Restenosis and Maintain Vessel Patency: Twelve-Month Results of the DEFINITIVE AR Study.
Topics: Aged; Angioplasty, Balloon; Atherectomy; Cardiovascular Agents; Coated Materials, Biocompatible; Equipment Design; Europe; Female; Humans; Intermittent Claudication; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Pilot Projects; Prospective Studies; Recurrence; Risk Factors; Stents; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Calcification; Vascular Patency | 2017 |
Treatment of femoropopliteal atherosclerotic lesions using the ranger paclitaxel-coated balloon catheter: 12-month results from an all-comers registry.
Topics: Aged; Angioplasty, Balloon; Atherosclerosis; Female; Femoral Artery; Follow-Up Studies; Germany; Hemodynamics; Humans; Male; Paclitaxel; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Popliteal Artery; Prospective Studies; Registries; Stents; Switzerland; Treatment Outcome; Ultrasonography, Doppler, Duplex; Vascular Patency | 2018 |
Stellarex drug-coated balloon for treatment of femoropopliteal arterial disease-The ILLUMENATE Global Study: 12-Month results from a prospective, multicenter, single-arm study.
Topics: Aged; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Female; Femoral Artery; Humans; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Prosthesis Design; Recovery of Function; Regional Blood Flow; Time Factors; Treatment Outcome; Vascular Access Devices | 2018 |
Treatment Effect of Drug-Coated Balloons Is Durable to 3 Years in the Femoropopliteal Arteries: Long-Term Results of the IN.PACT SFA Randomized Trial.
Topics: Aged; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Equipment Design; Europe; Female; Femoral Artery; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Single-Blind Method; Time Factors; Treatment Outcome; United States; Vascular Access Devices; Vascular Patency | 2018 |
12-Month Results From the First-in-Human Randomized Study of the Ranger Paclitaxel-Coated Balloon for Femoropopliteal Treatment.
Topics: Aged; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Europe; Female; Femoral Artery; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Recurrence; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2018 |
A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial.
Topics: Adult; Aged; Angiography; Drug-Eluting Stents; Endovascular Procedures; Female; Femoral Artery; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Polymers; Popliteal Artery; Single-Blind Method; Surface Properties; Tubulin Modulators; Vascular Patency | 2018 |
Drug-Coated Balloon Treatment for Femoropopliteal Artery Disease.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Equipment Design; Female; Femoral Artery; Humans; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Duplex; Vascular Access Devices | 2018 |
Drug-Coated Balloon Angioplasty Compared With Uncoated Balloons in the Treatment of 200 Chinese Patients With Severe Femoropopliteal Lesions: 24-Month Results of AcoArt I.
Topics: Aged; Angioplasty, Balloon; Cardiovascular Agents; China; Coated Materials, Biocompatible; Equipment Design; Female; Femoral Artery; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2018 |
Sustainable Antirestenosis Effect With a Low-Dose Drug-Coated Balloon: The ILLUMENATE European Randomized Clinical Trial 2-Year Results.
Topics: Aged; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Equipment Design; Europe; Female; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Prospective Studies; Recurrence; Risk Factors; Single-Blind Method; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2018 |
Clinical Randomized Trial Evaluating Novel, Microcrystalline, and Biocompatible Polymer Paclitaxel-Coated Balloon for the Treatment of Femoropopliteal Occlusive Disease: The BIOPAC Trial.
Topics: Aged; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Female; Femoral Artery; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Poland; Popliteal Artery; Prospective Studies; Single-Blind Method; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2018 |
Drug-Coated Balloon Treatment for Femoropopliteal Artery Disease: The Chronic Total Occlusion Cohort in the IN.PACT Global Study.
Topics: Aged; Amputation, Surgical; Angioplasty, Balloon; Cardiovascular Agents; Chronic Disease; Coated Materials, Biocompatible; Constriction, Pathologic; Equipment Design; Female; Femoral Artery; Humans; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Progression-Free Survival; Prospective Studies; Recurrence; Risk Assessment; Risk Factors; Time Factors; Vascular Access Devices; Vascular Patency | 2019 |
Long-Term Clinical Effectiveness of a Drug-Coated Balloon for the Treatment of Femoropopliteal Lesions.
Topics: Amputation, Surgical; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Femoral Artery; Humans; Limb Salvage; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Progression-Free Survival; Prospective Studies; Risk Factors; Single-Blind Method; Time Factors; Vascular Access Devices; Vascular Patency | 2019 |
Drug-Coated vs Uncoated Percutaneous Transluminal Angioplasty in Infrapopliteal Arteries: Six-Month Results of the Lutonix BTK Trial.
Topics: Aged; Angiography; Angioplasty; Coated Materials, Biocompatible; Female; Follow-Up Studies; Humans; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Time Factors; Treatment Outcome | 2019 |
Treatment of femoropopliteal in-stent restenosis with paclitaxel-eluting stents.
Topics: Aged; Alloys; Angioplasty, Balloon; Ankle Brachial Index; Canada; Cardiovascular Agents; Constriction, Pathologic; Disease-Free Survival; Drug-Eluting Stents; Europe; Exercise Test; Female; Femoral Artery; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Prosthesis Design; Prosthesis Failure; Recurrence; Registries; Republic of Korea; Risk Factors; Surveys and Questionnaires; Time Factors; Treatment Outcome; Vascular Patency | 2013 |
Drug-eluting balloon in peripheral intervention for the superficial femoral artery: the DEBATE-SFA randomized trial (drug eluting balloon in peripheral intervention for the superficial femoral artery).
Topics: Aged; Aged, 80 and over; Alloys; Amputation, Surgical; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Disease-Free Survival; Equipment Design; Female; Femoral Artery; Humans; Italy; Kaplan-Meier Estimate; Limb Salvage; Male; Paclitaxel; Peripheral Arterial Disease; Prospective Studies; Radiography; Recurrence; Risk Factors; Stents; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2013 |
High-grade, non-flow-limiting dissections do not negatively impact long-term outcome after paclitaxel-coated balloon angioplasty: an additional analysis from the THUNDER study.
Topics: Aged; Angioplasty, Balloon; Aortic Dissection; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Double-Blind Method; Equipment Design; Female; Femoral Artery; Germany; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Radiography; Recurrence; Regional Blood Flow; Retreatment; Risk Factors; Stents; Time Factors; Treatment Outcome; Vascular Access Devices | 2013 |
The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Drug Carriers; Equipment Design; Europe; Female; Femoral Artery; Humans; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Polysorbates; Popliteal Artery; Radiography; Secondary Prevention; Sorbitol; Time Factors; Treatment Outcome; Vascular Access Devices | 2014 |
Paclitaxel-coated balloon angioplasty versus drug-eluting stenting for the treatment of infrapopliteal long-segment arterial occlusive disease: the IDEAS randomized controlled trial.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Angiography, Digital Subtraction; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Drug-Eluting Stents; Female; Greece; Humans; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Prosthesis Design; Recurrence; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency; Vascular Remodeling | 2014 |
Two-year analysis of the Japanese cohort from the Zilver PTX randomized controlled trial supports the validity of multinational clinical trials.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Cardiovascular Agents; Constriction, Pathologic; Disease-Free Survival; Drug-Eluting Stents; Female; Femoral Artery; Germany; Humans; Japan; Kaplan-Meier Estimate; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Prosthesis Design; Prosthesis Failure; Reproducibility of Results; Research Design; Time Factors; Treatment Outcome; United States; Vascular Patency | 2014 |
Bare metal stent versus paclitaxel eluting stent for intermediate length femoropopliteal arterial lesions (BATTLE trial): study protocol for a randomized controlled trial.
Topics: Cardiovascular Agents; Clinical Protocols; Constriction, Pathologic; Drug-Eluting Stents; Endovascular Procedures; Femoral Artery; France; Humans; Metals; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Prosthesis Design; Recurrence; Research Design; Stents; Switzerland; Time Factors; Treatment Outcome | 2014 |
Angioplasty of femoral-popliteal arteries with drug-coated balloons: 5-year follow-up of the THUNDER trial.
Topics: Aged; Amputation, Surgical; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Equipment Design; Female; Femoral Artery; Humans; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Predictive Value of Tests; Radiography; Recurrence; Risk Factors; Sex Factors; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Duplex; Vascular Access Devices | 2015 |
Two-year results of a low-dose drug-coated balloon for revascularization of the femoropopliteal artery: outcomes from the ILLUMENATE first-in-human study.
Topics: Aged; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Disease-Free Survival; Female; Femoral Artery; Germany; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Prosthesis Design; Radiography; Recurrence; Risk Factors; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2015 |
Paclitaxel-releasing balloon in femoropopliteal lesions using a BTHC excipient: twelve-month results from the BIOLUX P-I randomized trial.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Ankle Brachial Index; Austria; Butyrates; Cardiovascular Agents; Coated Materials, Biocompatible; Excipients; Female; Femoral Artery; Follow-Up Studies; Germany; Humans; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Radiography; Treatment Outcome | 2015 |
Drug-coated balloons to improve femoropopliteal artery patency: Rationale and design of the LEVANT 2 trial.
Topics: Aged; Angioplasty, Balloon; Antineoplastic Agents, Phytogenic; Coated Materials, Biocompatible; Drug-Eluting Stents; Female; Femoral Artery; Follow-Up Studies; Humans; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Single-Blind Method; Treatment Outcome; Vascular Patency | 2015 |
Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease.
Topics: Aged; Angioplasty, Balloon; Diabetes Complications; Female; Femoral Artery; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Radiography; Single-Blind Method; Smoking; Vascular Patency | 2015 |
Strut Coverage After Paclitaxel-Eluting Stent Implantation in the Superficial Femoral Artery.
Topics: Cardiovascular Agents; Drug-Eluting Stents; Endovascular Procedures; Femoral Artery; Humans; Neointima; Paclitaxel; Peripheral Arterial Disease; Prospective Studies; Prosthesis Design; Time Factors; Tomography, Optical Coherence; Treatment Outcome; Wound Healing | 2016 |
Paclitaxel-Coated Balloon in Infrapopliteal Arteries: 12-Month Results From the BIOLUX P-II Randomized Trial (BIOTRONIK'S-First in Man study of the Passeo-18 LUX drug releasing PTA Balloon Catheter vs. the uncoated Passeo-18 PTA balloon catheter in subjec
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amputation, Surgical; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Critical Illness; Equipment Design; Female; Humans; Intermittent Claudication; Ischemia; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Radiography; Recurrence; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency; Young Adult | 2015 |
Zilver PTX Post-Market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 12-Month Results.
Topics: Aged; Drug-Eluting Stents; Female; Femoral Artery; Follow-Up Studies; Humans; Japan; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Product Surveillance, Postmarketing; Prospective Studies; Vascular Patency | 2016 |
German Center Subanalysis of the LEVANT 2 Global Randomized Study of the Lutonix Drug-Coated Balloon in the Treatment of Femoropopliteal Occlusive Disease.
Topics: Aged; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Female; Femoral Artery; Germany; Humans; Intermittent Claudication; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Recurrence; Single-Blind Method; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2016 |
Twelve-Month Results From the MAJESTIC Trial of the Eluvia Paclitaxel-Eluting Stent for Treatment of Obstructive Femoropopliteal Disease.
Topics: Aged; Alloys; Ankle Brachial Index; Australia; Blood Flow Velocity; Cardiovascular Agents; Chronic Disease; Constriction, Pathologic; Drug-Eluting Stents; Endovascular Procedures; Europe; Female; Femoral Artery; Humans; Ischemia; Kaplan-Meier Estimate; Limb Salvage; Male; Middle Aged; New Zealand; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Prosthesis Design; Regional Blood Flow; Self Expandable Metallic Stents; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Duplex; Vascular Patency | 2016 |
Paclitaxel-Eluting Balloon Versus Standard Balloon Angioplasty in In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Artery: 1-Year Results of the PACUBA Trial.
Topics: Aged; Angioplasty, Balloon; Ankle Brachial Index; Austria; Cardiovascular Agents; Coated Materials, Biocompatible; Equipment Design; Female; Femoral Artery; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Recurrence; Retreatment; Risk Factors; Single-Blind Method; Stents; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2016 |
Acotec Drug-Coated Balloon Catheter: Randomized, Multicenter, Controlled Clinical Study in Femoropopliteal Arteries: Evidence From the AcoArt I Trial.
Topics: Aged; Amputation, Surgical; Angiography; Angioplasty, Balloon; Ankle Brachial Index; Cardiovascular Agents; China; Coated Materials, Biocompatible; Equipment Design; Female; Femoral Artery; Humans; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Recurrence; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2016 |
Paclitaxel-coated versus plain old balloon angioplasty for the treatment of infrainguinal arterial disease in diabetic patients: the Belgian diabetic IN.PACT Trial.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Belgium; Cardiovascular Agents; Coated Materials, Biocompatible; Diabetic Angiopathies; Equipment Design; Female; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Prospective Studies; Recurrence; Risk Factors; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2017 |
Local Ultrasound to Enhance Paclitaxel Delivery After Femoral-Popliteal Treatment in Critical Limb Ischemia: The PACUS Trial.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Cardiovascular Agents; Catheterization, Peripheral; Coated Materials, Biocompatible; Constriction, Pathologic; Critical Illness; Equipment Design; Female; Femoral Artery; Humans; Ischemia; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Single-Blind Method; Time Factors; Treatment Outcome; Ultrasonic Therapy; Ultrasonography, Interventional; Vascular Access Devices; Vascular Patency | 2016 |
The effectiveness of the paclitaxel-coated Luminor® balloon catheter versus an uncoated balloon catheter in superficial femoral and popliteal arteries in preventing vessel restenosis or reocclusion: study protocol for a randomized controlled trial.
Topics: Angiography, Digital Subtraction; Angioplasty, Balloon; Ankle Brachial Index; Cardiovascular Agents; Clinical Protocols; Coated Materials, Biocompatible; Computed Tomography Angiography; Constriction, Pathologic; Exercise Tolerance; Female; Femoral Artery; Germany; Humans; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Quality of Life; Recovery of Function; Recurrence; Research Design; Risk Factors; Surveys and Questionnaires; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Duplex; Vascular Access Devices; Vascular Patency; Walking | 2016 |
Drug-eluting stenting for femoropopliteal lesions, followed by cilostazol treatment, reduces stent restenosis in patients with symptomatic peripheral artery disease.
Topics: Aged; Aged, 80 and over; Cardiovascular Agents; Cilostazol; Constriction, Pathologic; Drug-Eluting Stents; Endovascular Procedures; Female; Femoral Artery; Humans; Japan; Logistic Models; Male; Middle Aged; Odds Ratio; Paclitaxel; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Popliteal Artery; Propensity Score; Prospective Studies; Prosthesis Design; Recurrence; Registries; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Duplex; Vascular Patency | 2017 |
Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results.
Topics: Aged; Angioplasty, Balloon; Blood Vessel Prosthesis Implantation; Disease-Free Survival; Drug-Eluting Stents; Female; Femoral Artery; Follow-Up Studies; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Treatment Outcome; Vascular Patency | 2011 |
The Zilver® PTX® Single Arm Study: 12-month results from the TASC C/D lesion subgroup.
Topics: Aged; Drug-Eluting Stents; Endovascular Procedures; Female; Femoral Artery; Follow-Up Studies; Humans; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Prosthesis Design; Time Factors; Treatment Outcome; Vascular Patency | 2013 |
213 other study(ies) available for paclitaxel and Peripheral Arterial Diseases
Article | Year |
---|---|
Mortality Following Treatment with Paclitaxel-Coated Devices in Real World Utilization: Correlation to Total Lifetime Dosage?
Topics: Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Retrospective Studies; Treatment Outcome | 2021 |
Mortality is not associated with paclitaxel-coated devices usage in peripheral arterial disease of lower extremities.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Angioplasty, Balloon; Comorbidity; Female; Humans; Leg; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Postoperative Complications; Stents | 2021 |
Clinical outcomes and predictors of restenosis in patients with femoropopliteal artery disease treated using polymer-coated paclitaxel-eluting stents or drug-coated balloons.
Topics: Angioplasty, Balloon; Coated Materials, Biocompatible; Drug-Eluting Stents; Female; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Polymers; Popliteal Artery; Stents; Time Factors; Treatment Outcome; Vascular Patency | 2022 |
Real-World Clinical Outcomes of IN.PACT Admiral Drug-Coated Balloon for Femoropopliteal Artery Disease - 12-Month Results From Japan Post-Market Surveillance Study.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Femoral Artery; Humans; Japan; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2021 |
A novel paclitaxel coated balloon with increased drug transfer for treatment of complex vascular lesions.
Topics: Angioplasty, Balloon; Animals; Cardiovascular Agents; Coated Materials, Biocompatible; Paclitaxel; Peripheral Arterial Disease; Swine; Vascular Access Devices | 2021 |
The Gordian Knot of Paclitaxel Devices in the Lower Limbs.
Topics: Humans; Lower Extremity; Paclitaxel; Peripheral Arterial Disease; Treatment Outcome | 2021 |
Drug-Coated Balloon Angioplasty Versus Standard Uncoated Balloon Angioplasty for Long Femoropopliteal Lesions: Post Hoc Analysis of the 24-Month Results of the AcoArt I Study.
Topics: Angioplasty, Balloon; Coated Materials, Biocompatible; Constriction, Pathologic; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Time Factors; Treatment Outcome; Vascular Patency | 2022 |
Pathography of Superficial Femoral Artery Treated With ELUVIA
Topics: Cardiovascular Agents; Drug-Eluting Stents; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Treatment Outcome | 2022 |
Impact of Cardiac Function on Loss of Patency in Patients With Peripheral Artery Disease Presenting the Femoropopliteal Lesions Endovascularly Treated With New-Generation Devices.
Topics: Aged; Aged, 80 and over; Drug-Eluting Stents; Femoral Artery; Heart Failure; Humans; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Retrospective Studies; Risk Factors; Treatment Outcome; Vascular Patency | 2023 |
Assessment of 2-Year Mortality With Use of Drug-Coated Devices in Femoropopliteal Disease: A Real-World Experience From the Bronx, New York.
Topics: Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Femoral Artery; Humans; New York; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Retrospective Studies; Treatment Outcome | 2022 |
Intravascular Lithotripsy and Drug-Coated Balloon Angioplasty for Severely Calcified Femoropopliteal Arterial Disease.
Topics: Angioplasty, Balloon; Calcium; Coated Materials, Biocompatible; Femoral Artery; Humans; Ischemia; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Time Factors; Treatment Outcome; Vascular Patency | 2023 |
2-Year Results With a Sirolimus-Eluting Self-Expanding Stent for Femoropopliteal Lesions: The First-in-Human ILLUMINA Study.
Topics: Cardiovascular Agents; Drug-Eluting Stents; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Sirolimus; Stents; Treatment Outcome; Vascular Patency | 2022 |
More Food for Thought for Use of Paclitaxel in the Below-the-Knee Arena in the Setting of Critical Limb Ischemia.
Topics: Angioplasty, Balloon; Chronic Limb-Threatening Ischemia; Humans; Ischemia; Leg; Lower Extremity; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Treatment Outcome; Vascular Patency | 2022 |
Paclitaxel in real-life data is not associated with reduced survival but has limited benefit in preventing amputation.
Topics: Amputation, Surgical; Female; Femoral Artery; Humans; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Risk Factors; Survival Analysis | 2022 |
Femoropopliteal Drug-coated Balloon Angioplasty: Long-term Results of the Randomized EffPac Trial.
Topics: Angioplasty, Balloon; Coated Materials, Biocompatible; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Treatment Outcome; Vascular Patency | 2022 |
Perioperative Inflammatory Status Predicts Mid-Term Outcomes in Patients Undergoing Femoropopliteal Paclitaxel-Coated Balloon Angioplasty.
Topics: Aged; Angioplasty, Balloon; C-Reactive Protein; Coated Materials, Biocompatible; Female; Femoral Artery; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Retrospective Studies; Treatment Outcome; Vascular Patency | 2022 |
Studying the effect of drug-to-excipient ratio on drug release profile for drug coated balloons.
Topics: Antineoplastic Agents; Coated Materials, Biocompatible; Drug Liberation; Excipients; Humans; Paclitaxel; Peripheral Arterial Disease; Treatment Outcome | 2022 |
Sex-Related Outcomes Following Drug Balloon Angioplasty in Patients from the BIOLUX P-III Registry: A Subgroup Analysis.
Topics: Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Female; Femoral Artery; Humans; Limb Salvage; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Registries; Treatment Outcome; Vascular Patency | 2022 |
Optimal Intraluminal Drug-Coated Balloon Versus Drug-Eluting Stent in Patients With Chronic Total Occlusion of the Superficial Femoral Artery: A Retrospective Analysis.
Topics: Angioplasty, Balloon; Arterial Occlusive Diseases; Coated Materials, Biocompatible; Drug-Eluting Stents; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Retrospective Studies; Treatment Outcome; Vascular Patency | 2022 |
Update From the Longitudinal Assessment of Safety of Femoropopliteal Endovascular Treatment With Paclitaxel-Coated Devices Among Medicare Beneficiaries: The SAFE-PAD Study.
Topics: Aged; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Femoral Artery; Humans; Medicare; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Treatment Outcome; United States | 2022 |
Paclitaxel-coated balloons for femoropopliteal peripheral arterial disease: final five-year results of the IN.PACT Global Study.
Topics: Angioplasty, Balloon; Female; Femoral Artery; Humans; Male; Paclitaxel; Peripheral Arterial Disease; Randomized Controlled Trials as Topic; Treatment Outcome | 2022 |
Use of paclitaxel-coated balloons in clinical setting is not associated with increased mortality compared with plain balloon angioplasty in femoropopliteal lesions.
Topics: Angioplasty, Balloon; Anticoagulants; Cardiovascular Agents; Coated Materials, Biocompatible; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Retrospective Studies; Treatment Outcome | 2022 |
Efficacy and Safety Differences between Domestic Paclitaxel Drug-Coated Balloons and Metal Bare Stents in the Treatment of ASO of Femoral-Popliteal Arteries Type IIA-C.
Topics: Arteriosclerosis Obliterans; Coated Materials, Biocompatible; Constriction, Pathologic; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Retrospective Studies; Stents; Treatment Outcome | 2022 |
Long-Term Outcomes of the 150 mm Drug-Coated Balloon Cohort from the IN.PACT Global Study.
Topics: Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Cohort Studies; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Time Factors; Vascular Access Devices; Vascular Patency | 2022 |
Delayed rupture of superficial femoral arterial aneurysm at the fluoropolymer-based paclitaxel-eluting stent implanted site.
Topics: Aneurysm; Drug-Eluting Stents; Femoral Artery; Fluorocarbon Polymers; Humans; Paclitaxel; Peripheral Arterial Disease; Stents; Treatment Outcome | 2023 |
Safety and Efficacy of All Comers Treated with a Paclitaxel Coated Balloon for Below Knee Intervention.
Topics: Amputation, Surgical; Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Coated Materials, Biocompatible; Cohort Studies; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Treatment Outcome; Vascular Patency | 2022 |
Nanoparticle coatings for controlled release of quercetin from an angioplasty balloon.
Topics: Angioplasty, Balloon; Coated Materials, Biocompatible; Delayed-Action Preparations; Humans; Nanoparticles; Paclitaxel; Peripheral Arterial Disease; Polymers; Quercetin | 2022 |
Safety of Paclitaxel Coated Devices: Is the Quest Completed?
Topics: Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Treatment Outcome | 2023 |
Determinants of Drug-Coated Balloon Failure in Patients Undergoing Femoropopliteal Arterial Intervention.
Topics: Aged; Angioplasty, Balloon; Carcinoma, Renal Cell; Coated Materials, Biocompatible; Constriction, Pathologic; Female; Femoral Artery; Humans; Kidney Neoplasms; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2022 |
Two-year clinical outcomes and predictors of restenosis following the use of polymer-coated paclitaxel-eluting stents or drug-coated balloons in patients with femoropopliteal artery disease.
Topics: Angioplasty, Balloon; Coated Materials, Biocompatible; Constriction, Pathologic; Drug-Eluting Stents; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Retrospective Studies; Stents; Treatment Outcome; Vascular Patency | 2023 |
Paclitaxel Therapy in Peripheral Arterial Disease: Back to the Future?
Topics: Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Treatment Outcome | 2022 |
Comparison Between Clinical Outcomes of Low- and High-Dose Paclitaxel Drug-Coated Balloon in Endovascular Therapy for Femoropopliteal Lesion.
Topics: Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Time Factors; Treatment Outcome; Vascular Patency | 2023 |
Comparison of Drug-Coated Balloons vs Bare-Metal Stents in Patients With Femoropopliteal Arterial Disease.
Topics: Angioplasty, Balloon; Coated Materials, Biocompatible; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Stents; Treatment Outcome; Vascular Patency | 2023 |
Long-term outcomes after paclitaxel-coated balloon angioplasty of femoropopliteal arteries in Asian patients of the IN.PACT Global Study.
Topics: Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2022 |
Effect of Paclitaxel Drug-Coated Balloon Angioplasty of Infrapopliteal Lesions on Mortality.
Topics: Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Retrospective Studies; Time Factors; Treatment Outcome; Vascular Patency | 2022 |
Drug-coated balloon treatment of complex femoropopliteal disease yields favorable and durable outcomes at 5 years.
Topics: Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Treatment Outcome; Vascular Patency | 2022 |
Real-world outcomes of Cook Zilver PTX in femoro-popliteal district from multicenter experience.
Topics: Aged; Chronic Limb-Threatening Ischemia; Coronary Artery Disease; Drug-Eluting Stents; Femoral Artery; Humans; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prosthesis Design; Retrospective Studies; Treatment Outcome; Vascular Patency | 2023 |
Outcome after revascularization with paclitaxel-coated devices in patients with chronic limb-threatening ischemia.
Topics: Chronic Limb-Threatening Ischemia; Femoral Artery; Humans; Ischemia; Limb Salvage; Paclitaxel; Peripheral Arterial Disease; Retrospective Studies; Risk Factors; Treatment Outcome; Vascular Patency | 2023 |
Safety and Efficacy of the Passeo-18 Lux Drug-Coated Balloon Catheter in Atherosclerotic Femoropopliteal Lesions: The Multicenter BIOLUX P-IV China Study.
Topics: Aged; Angioplasty, Balloon; Atherosclerosis; Catheters; China; Coated Materials, Biocompatible; Constriction, Pathologic; Femoral Artery; Humans; Limb Salvage; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Treatment Outcome; Vascular Patency | 2023 |
Superficial Femoral Artery in-Stent Restenosis Treated with Paclitaxel-Coated Balloon Angioplasty - Results of Three-Year Follow-Up.
Topics: Angioplasty, Balloon; Coated Materials, Biocompatible; Constriction, Pathologic; Coronary Restenosis; Femoral Artery; Follow-Up Studies; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Treatment Outcome; Vascular Patency | 2023 |
Real-World Safety Analysis of Paclitaxel Devices Used for the Treatment of Peripheral Artery Disease.
Topics: Cardiovascular Agents; Drug-Eluting Stents; Endovascular Procedures; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Treatment Outcome; Vascular Patency | 2023 |
Cost-Effectiveness of Drug-Coated Balloon Angioplasty versus Plain Old Balloon Angioplasty for Arteriovenous Fistula Stenosis.
Topics: Aged; Angioplasty, Balloon; Arteriovenous Fistula; Coated Materials, Biocompatible; Constriction, Pathologic; Cost-Benefit Analysis; Humans; Medicare; Paclitaxel; Peripheral Arterial Disease; Treatment Outcome; United States | 2023 |
Local, Downstream, and Systemic Evaluation after Femoral Artery Angioplasty with Kanshas Drug-Coated Balloons In Vitro and in a Healthy Swine Model.
Topics: Angioplasty, Balloon; Animals; Cardiovascular Agents; Femoral Artery; Paclitaxel; Peripheral Arterial Disease; Swine | 2023 |
Propensity score-matched analysis of six-month outcomes of paclitaxel-coated balloons combined with UltraScore balloons versus conventional scoring balloons for femoropopliteal lesions.
Topics: Angioplasty, Balloon; Constriction, Pathologic; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Propensity Score; Retrospective Studies; Treatment Outcome; Vascular Patency | 2023 |
Clinical investigation of the GORE drug-coated PTA balloon catheter for CE mark approval.
Topics: Aged; Angioplasty, Balloon; Coated Materials, Biocompatible; Female; Femoral Artery; Humans; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Treatment Outcome; Urinary Catheters; Vascular Access Devices | 2023 |
Drug-Coated Balloon for the Treatment of Long-Segment Femoropopliteal Artery Disease: Pooled Analysis from the BIOLUX P-III SPAIN and BIOLUX P-III All-Comers Registry Long Lesion Subgroup.
Topics: Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Femoral Artery; Humans; Limb Salvage; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Registries; Spain; Treatment Outcome; Vascular Patency | 2023 |
Re-analysis of Old Data and New Outcomes Data Do Not Support a Link Between Paclitaxel Coated Balloons and Paclitaxel Eluting Stents and Mortality: These Devices Should be Used in PAD (Peripheral Arterial Disease) Treatment in Femoropopliteal Disease on t
Topics: Angioplasty, Balloon; Coated Materials, Biocompatible; Drug-Eluting Stents; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Stents; Treatment Outcome | 2023 |
Drug-Coated Balloons for Complex PAD: More Study Is Needed.
Topics: Angioplasty, Balloon; Coated Materials, Biocompatible; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Treatment Outcome | 2023 |
Reply: Drug-Coated Balloons for Complex PAD: More Study Is Needed.
Topics: Angioplasty, Balloon; Coated Materials, Biocompatible; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Treatment Outcome | 2023 |
Creep of Calcium Nodules Through Struts of Paclitaxel-Eluting Stent in Distal Superficial Femoral Artery.
Topics: Calcium; Cardiovascular Agents; Drug-Eluting Stents; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Stents; Tomography, Optical Coherence; Treatment Outcome | 2023 |
Long-term Outcome with Paclitaxel Drug-coated Balloon in the Real World: Focus on Those Most at Risk.
Topics: Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Coated Materials, Biocompatible; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Treatment Outcome | 2023 |
Low-Dose Paclitaxel-Coated Balloons for Femoropopliteal Disease: Days of Future Past?
Topics: Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Treatment Outcome; Vascular Patency | 2023 |
Paclitaxel-coated balloons are safe for the treatment of arterial stenoses.
Topics: Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Treatment Outcome; Vascular Diseases | 2023 |
Assessment of Vascular Patency and Inflammation with Intravascular Optical Coherence Tomography in Patients with Superficial Femoral Artery Disease Treated with Zilver PTX Stents.
Topics: Aged; Aged, 80 and over; Alloys; Angioplasty, Balloon; Cardiovascular Agents; Drug-Eluting Stents; Female; Femoral Artery; Humans; Inflammation; Male; Middle Aged; Neointima; Paclitaxel; Peripheral Arterial Disease; Predictive Value of Tests; Prospective Studies; Prosthesis Design; Risk Factors; Self Expandable Metallic Stents; Time Factors; Tomography, Optical Coherence; Treatment Outcome; Vascular Patency; Vascular Remodeling | 2020 |
Mortality Risk Following Application of a Paclitaxel-Coated Stent in Femoropopliteal Lesions.
Topics: Aged; Aged, 80 and over; Cardiovascular Agents; Drug-Eluting Stents; Endovascular Procedures; Female; Femoral Artery; Humans; Japan; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prosthesis Design; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2019 |
Development of drug-coated balloon for the treatment of multiple peripheral artery segments.
Topics: Angioplasty, Balloon; Animals; Cardiovascular Agents; Coated Materials, Biocompatible; Disease Models, Animal; Paclitaxel; Particulate Matter; Peripheral Arterial Disease; Swine; Vascular Patency | 2020 |
Safety of Paclitaxel-Coated Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Cardiovascular Agents; Cause of Death; Coated Materials, Biocompatible; Female; Femoral Artery; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Vascular Patency | 2019 |
Mortality after use of paclitaxel-based devices in peripheral arteries: a real-world safety analysis.
Topics: Cardiovascular Agents; Drug-Eluting Stents; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Stents; Treatment Outcome | 2020 |
The Market Reacts Quickly: Changes in Paclitaxel Vascular Device Purchasing Within the Ascension Healthcare System.
Topics: Antineoplastic Agents, Phytogenic; Coated Materials, Biocompatible; Consumer Product Safety; Drug-Eluting Stents; Endovascular Procedures; Graft Occlusion, Vascular; Humans; Long Term Adverse Effects; Meta-Analysis as Topic; Neointima; Paclitaxel; Peripheral Arterial Disease; Product Surveillance, Postmarketing | 2020 |
Midterm Outcomes of Drug-Coated Balloon Angioplasty in Femoropopliteal Lesions in a Daily Practice Cohort.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Female; Femoral Artery; Humans; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2020 |
Comparison Between Interwoven Nitinol and Drug Eluting Stents for Endovascular Treatment of Femoropopliteal Artery Disease.
Topics: Aged; Aged, 80 and over; Alloys; Angiography, Digital Subtraction; Blood Vessel Prosthesis Implantation; Drug-Eluting Stents; Endovascular Procedures; Female; Femoral Artery; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prosthesis Design; Retrospective Studies; Self Expandable Metallic Stents; Treatment Outcome; Vascular Calcification | 2019 |
Has the Paclitaxel Signal Changed From Red to Green?
Topics: Angioplasty; Angioplasty, Balloon; Humans; Knee Joint; Paclitaxel; Peripheral Arterial Disease | 2020 |
Turbo-Power™ Laser Atherectomy Combined with Drug-coated Balloon Angioplasty is Associated with Improved One-Year Outcomes for the Treatment of Tosaka II and III Femoropopliteal In-stent Restenosis.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Atherectomy; California; Cardiovascular Agents; Coated Materials, Biocompatible; Colorado; Constriction, Pathologic; Female; Femoral Artery; Humans; Laser Therapy; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Recurrence; Retrospective Studies; Stents; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2020 |
Statistical Alchemy and the Road Ahead.
Topics: Alchemy; Angioplasty, Balloon; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Treatment Outcome | 2019 |
Primary Patency of Long-Segment Femoropopliteal Artery Lesions in Patients with Peripheral Arterial Occlusive Disease Treated with Paclitaxel-Eluting Technology.
Topics: Aged; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Critical Illness; Databases, Factual; Drug-Eluting Stents; Female; Femoral Artery; Humans; Ischemia; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prosthesis Design; Recurrence; Retrospective Studies; Time Factors; Treatment Outcome; Vascular Patency | 2020 |
Rigorous focus on paclitaxel-related mortality in femoropopliteal artery disease.
Topics: Angioplasty, Balloon; Coated Materials, Biocompatible; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery | 2020 |
Paclitaxel-coated peripheral artery devices are not associated with increased mortality.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Atherectomy; Cardiovascular Agents; Coated Materials, Biocompatible; Drug-Eluting Stents; Female; Femoral Artery; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prosthesis Design; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2020 |
Editor's Choice - Long Term Survival after Femoropopliteal Artery Revascularisation with Paclitaxel Coated Devices: A Propensity Score Matched Cohort Analysis.
Topics: Aged; Aged, 80 and over; Cardiovascular Agents; Constriction, Pathologic; Female; Femoral Artery; Humans; Intermittent Claudication; Ischemia; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Retrospective Studies; Vascular Access Devices | 2020 |
Development of an automated micropipette coating method for drug-coated balloons.
Topics: Antineoplastic Agents; Arteries; Biological Transport; Coated Materials, Biocompatible; Drug Carriers; Drug Compounding; Drug Liberation; Excipients; Humans; Paclitaxel; Peripheral Arterial Disease; Polyethylene Glycols; Reproducibility of Results; Treatment Outcome; Vascular Access Devices | 2020 |
Paclitaxel-Coated Balloon for the Treatment of Infrainguinal Disease: 12-Month Outcomes in the All-Comers Cohort of BIOLUX P-III Global Registry.
Topics: Aged; Amputation, Surgical; Angioplasty, Balloon; Asia; Australia; Cardiovascular Agents; Coated Materials, Biocompatible; Equipment Design; Europe; Female; Femoral Artery; Humans; Limb Salvage; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Progression-Free Survival; Prospective Studies; Registries; Time Factors; Vascular Access Devices; Vascular Patency | 2020 |
A universal drug delivery catheter for the treatment of infrapopliteal arterial disease using liquid therapy.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Angioplasty, Balloon; Cardiovascular Agents; Drug Delivery Systems; Feasibility Studies; Female; Humans; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Risk Factors; Time Factors; Treatment Outcome; United States; Vascular Access Devices; Vascular Patency | 2020 |
Mortality After Paclitaxel Coated Balloon Angioplasty and Stenting of Superficial Femoral and Popliteal Artery in the Vascular Quality Initiative.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Cardiovascular Agents; Cause of Death; Coated Materials, Biocompatible; Drug-Eluting Stents; Female; Femoral Artery; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Quality Indicators, Health Care; Registries; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2020 |
Pre-Clinical Investigation of Keratose as an Excipient of Drug Coated Balloons.
Topics: Angioplasty, Balloon; Animals; Antineoplastic Agents; Cardiovascular Agents; Coated Materials, Biocompatible; Drug Carriers; Drug Delivery Systems; Drug Evaluation, Preclinical; Immunohistochemistry; Keratosis; Paclitaxel; Peripheral Arterial Disease | 2020 |
Surface Modification Using Ultraviolet-Ozone Treatment Enhances Acute Drug Transfer in Drug-Coated Balloon Therapy.
Topics: Cardiovascular Agents; Coated Materials, Biocompatible; Humans; Ozone; Paclitaxel; Peripheral Arterial Disease; Pharmaceutical Preparations; Time Factors; Treatment Outcome | 2020 |
A Single-Center Experience of Paclitaxel in the Treatment of Femoropopliteal Disease-No Evidence for an Association With Mortality.
Topics: Aged; Aged, 80 and over; Cardiovascular Agents; Coated Materials, Biocompatible; Drug-Eluting Stents; Endovascular Procedures; Female; Femoral Artery; Humans; Male; Middle Aged; Newfoundland and Labrador; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prosthesis Design; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Vascular Access Devices | 2020 |
Paclitaxel-coated balloons in peripheral artery disease: how much is enough?
Topics: Angioplasty, Balloon; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Pharmaceutical Preparations; Prospective Studies | 2020 |
Paclitaxel and Mortality Following Peripheral Angioplasty: An Adjusted and Case Matched Multicentre Analysis.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Databases, Factual; Drug-Eluting Stents; England; Female; Femoral Artery; Greece; Humans; Intermittent Claudication; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prosthesis Design; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2020 |
US Food and Drug Administration Perspective on "Mortality and Paclitaxel-Coated Devices: An Individual Patient Data Meta-Analysis".
Topics: Angioplasty, Balloon; Humans; Paclitaxel; Peripheral Arterial Disease; United States; United States Food and Drug Administration | 2020 |
Kounis Syndrome after Angioplasty of the Superficial Femoral Artery with Paclitaxel-Coated Balloon.
Topics: Aged; Anaphylaxis; Angioplasty, Balloon; Cardiovascular Agents; Constriction, Pathologic; Drug Hypersensitivity; Female; Femoral Artery; Humans; Kounis Syndrome; Paclitaxel; Peripheral Arterial Disease; Treatment Outcome; Vascular Access Devices | 2020 |
Three-Year Sustained Clinical Efficacy of Drug-Coated Balloon Angioplasty in a Real-World Femoropopliteal Cohort.
Topics: Aged; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Female; Femoral Artery; Humans; Intermittent Claudication; Ischemia; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Recovery of Function; Registries; Severity of Illness Index; Time Factors; Treatment Outcome; Vascular Patency | 2020 |
Evaluation of Mortality Following Paclitaxel Drug-Coated Balloon Angioplasty of Femoropopliteal Lesions in the Real World.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Comorbidity; Equipment Design; Female; Femoral Artery; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Retrospective Studies; Risk Assessment; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome; Vascular Access Devices | 2020 |
Increased mortality with paclitaxel-eluting stents is driven by lesion length.
Topics: Aged; Cardiovascular Agents; Drug-Eluting Stents; Endovascular Procedures; Female; Femoral Artery; Humans; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prosthesis Design; Retreatment; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Vascular Patency | 2021 |
Stellarex drug-coated balloon: a technology evaluation.
Topics: Angioplasty, Balloon; Coated Materials, Biocompatible; Excipients; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Time Factors; Treatment Outcome | 2020 |
Two-year Review on Mortality and Morbidity after Femoropopliteal Drug-coated Balloon Angioplasty in the Randomized EffPac Trial.
Topics: Angioplasty, Balloon; Antineoplastic Agents, Phytogenic; Drug-Eluting Stents; Femoral Artery; Humans; Morbidity; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Randomized Controlled Trials as Topic | 2020 |
Paclitaxel-Coated Balloons and Stents for Lower Extremity Peripheral Arterial Disease Interventions: A Regulatory Perspective for the Practicing Clinician.
Topics: Angioplasty, Balloon; Blood Vessel Prosthesis; Drug-Eluting Stents; Endovascular Procedures; Humans; Leg; Medical Device Legislation; Paclitaxel; Peripheral Arterial Disease; Risk Assessment; United States; United States Food and Drug Administration | 2020 |
Influence of Self-Expanding Paclitaxel-Eluting Stent Sizing on Neointimal Hyperplasia in Superficial Femoral Artery Lesions.
Topics: Aged; Drug-Eluting Stents; Endovascular Procedures; Female; Femoral Artery; Follow-Up Studies; Humans; Hyperplasia; Male; Middle Aged; Neointima; Paclitaxel; Peripheral Arterial Disease; Prospective Studies; Prosthesis Design; Self Expandable Metallic Stents; Tomography, Optical Coherence; Treatment Outcome | 2020 |
Paclitaxel-Coated Peripheral Arterial Devices are Associated with Reduced Mortality in Younger Patients.
Topics: Age Factors; Aged; Aged, 80 and over; Angioplasty, Balloon; Atherectomy; Cardiovascular Agents; Drug-Eluting Stents; Female; Femoral Artery; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2021 |
Post-dilatation of an interwoven nitinol stent using a paclitaxel-coated balloon for revascularization of complex femoro-popliteal lesions.
Topics: Aged; Alloys; Angioplasty, Balloon; Female; Femoral Artery; Humans; Leg; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Prosthesis Design; Stents; Treatment Outcome; Ultrasonography, Doppler, Duplex | 2021 |
Long Term Outcomes After Revascularisations Below the Knee with Paclitaxel Coated Devices: A Propensity Score Matched Cohort Analysis.
Topics: Administrative Claims, Healthcare; Aged; Aged, 80 and over; Amputation, Surgical; Cardiovascular Agents; Chronic Disease; Coated Materials, Biocompatible; Databases, Factual; Drug-Eluting Stents; Endovascular Procedures; Female; Germany; Humans; Ischemia; Leg; Limb Salvage; Male; Paclitaxel; Peripheral Arterial Disease; Propensity Score; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2020 |
Paclitaxel exposure: Long-term safety and effectiveness of a drug-coated balloon for claudication in pooled randomized trials.
Topics: Aged; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Female; Humans; Intermittent Claudication; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Vascular Access Devices | 2020 |
Comparison of paclitaxel-coated balloon angioplasty with femoropopliteal bypass surgery in treating femoropopliteal lesions.
Topics: Aged; Angioplasty, Balloon; Blood Vessel Prosthesis Implantation; Cardiovascular Agents; Coated Materials, Biocompatible; Disease-Free Survival; Equipment Design; Female; Femoral Artery; Humans; Intermittent Claudication; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Retrospective Studies; Time Factors; Vascular Access Devices; Vascular Patency | 2021 |
Combining the Passeo-18 Lux Drug-Coated Balloon and the Pulsar-18 Bare Metal Stent: 12- and 24-Month Outcomes of the BIOLUX 4EVER Investigator-Initiated Trial.
Topics: Aged; Aged, 80 and over; Alloys; Angioplasty, Balloon; Belgium; Coated Materials, Biocompatible; Female; Femoral Artery; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Pharmaceutical Preparations; Popliteal Artery; Prospective Studies; Stents; Treatment Outcome; Vascular Patency | 2020 |
Combination of Percutaneous Rotational Thrombectomy and Drug-Coated Balloon for Treatment of Femoropopliteal Artery Nonembolic Occlusion: 12-Month Follow-up.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Angioplasty, Balloon; Beijing; Cardiovascular Agents; Female; Femoral Artery; Humans; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Recurrence; Retrospective Studies; Risk Factors; Thrombectomy; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2020 |
Evaluation of mortality following paclitaxel drug-coated stent angioplasty of femoropopliteal lesions in real world.
Topics: Aged; Aged, 80 and over; Comorbidity; Databases, Factual; Drug-Eluting Stents; Endovascular Procedures; Female; Femoral Artery; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prosthesis Design; Retrospective Studies; Risk Assessment; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome | 2020 |
Real-World Experience With a Paclitaxel-Coated Balloon in Critical Limb Ischemia: 24-Month Subgroup Outcomes of BIOLUX P-III.
Topics: Aged; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Humans; Ischemia; Limb Salvage; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Time Factors; Treatment Outcome; Vascular Patency | 2020 |
No Difference in Mid-term and Long-Term Mortality After Vascular Paclitaxel Exposure.
Topics: Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Drug-Eluting Stents; Finland; Humans; Paclitaxel; Peripheral Arterial Disease; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Vascular Access Devices | 2021 |
Prediction Model for Freedom from TLR from a Multi-study Analysis of Long-Term Results with the Zilver PTX Drug-Eluting Peripheral Stent.
Topics: Aged; Aged, 80 and over; Datasets as Topic; Drug-Eluting Stents; Endovascular Procedures; Female; Femoral Artery; Follow-Up Studies; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Recurrence; Time Factors; Treatment Outcome; Tubulin Modulators; Vascular Patency | 2021 |
Outcomes of treatment with paclitaxel-coated devices for peripheral arterial disease.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Cardiovascular Agents; Coated Materials, Biocompatible; Drug-Eluting Stents; Endovascular Procedures; Female; Humans; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Prosthesis Design; Retreatment; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Vascular Patency | 2021 |
Paclitaxel exposure and long-term mortality of patients treated with the Zilver PTX drug-eluting stent.
Topics: Aged; Aged, 80 and over; Cardiovascular Agents; Databases, Factual; Drug-Eluting Stents; Endovascular Procedures; Female; Femoral Artery; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Progression-Free Survival; Prosthesis Design; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Vascular Patency | 2021 |
Paclitaxel-Coated Balloon Angioplasty for the Treatment of Infrainguinal Arteries: 24-Month Outcomes in the Full Cohort of BIOLUX P-III Global Registry.
Topics: Aged; Angioplasty, Balloon; Coated Materials, Biocompatible; Cohort Studies; Endovascular Procedures; Equipment Design; Femoral Artery; Follow-Up Studies; Humans; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Registries; Time Factors; Treatment Outcome; Tubulin Modulators; Vascular Patency | 2021 |
Long-Term Effectiveness of a Drug-Eluting Stent for Femoropopliteal In-Stent Restenosis: Subanalysis of the Zilver PTX Japan Post-Market Surveillance Study.
Topics: Aged; Aged, 80 and over; Coronary Restenosis; Drug-Eluting Stents; Femoral Artery; Humans; Japan; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Stents; Treatment Outcome; Vascular Patency | 2021 |
Outcomes of Dissection Angles as Predictor of Restenosis after Drug-Coated Balloon Treatment.
Topics: Aged; Aged, 80 and over; Constriction, Pathologic; Endovascular Procedures; Female; Humans; Male; Paclitaxel; Peripheral Arterial Disease; Prognosis; Retrospective Studies; Treatment Outcome; Tubulin Modulators; Vascular Access Devices | 2021 |
Evaluation of mortality following paclitaxel drug-coated balloon angioplasty of femoropopliteal lesions in patients with ulcerations and gangrene - a single center experience.
Topics: Aged, 80 and over; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Femoral Artery; Gangrene; Humans; Paclitaxel; Peripheral Arterial Disease; Pharmaceutical Preparations; Popliteal Artery; Retrospective Studies; Treatment Outcome | 2021 |
Safety and efficacy of paclitaxel drug-coated balloon treatment of femoropopliteal claudicants: Data and analytic methods matter.
Topics: Angioplasty, Balloon; Coated Materials, Biocompatible; Drug-Eluting Stents; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Pharmaceutical Preparations; Popliteal Artery; Randomized Controlled Trials as Topic; Treatment Outcome | 2020 |
Drug-eluting stent, drug eluting balloon controversy in peripheral artery disease; what is the verdict?
Topics: Angioplasty; Drug-Eluting Stents; Humans; Paclitaxel; Peripheral Arterial Disease; Pharmaceutical Preparations; Treatment Outcome | 2020 |
Paclitaxel-coated devices in the treatment of femoropopliteal stenosis among patients ≥65 years old: An ACC PVI Registry Analysis.
Topics: Aged; Antineoplastic Agents, Phytogenic; Centers for Medicare and Medicaid Services, U.S.; Constriction, Pathologic; Drug-Eluting Stents; Female; Femoral Artery; Humans; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Registries; Time Factors; United States | 2021 |
Aneurysmal Degeneration After Paclitaxel-Eluting Balloon Angioplasty.
Topics: Aged; Aneurysm; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Graft Occlusion, Vascular; Humans; Male; Paclitaxel; Peripheral Arterial Disease; Treatment Outcome; Vascular Access Devices; Vascular Grafting | 2021 |
Long-term safety of drug-coated devices for peripheral revascularisation.
Topics: Aged; Angioplasty, Balloon; Coated Materials, Biocompatible; Femoral Artery; Humans; Medicare; Paclitaxel; Peripheral Arterial Disease; Pharmaceutical Preparations; Popliteal Artery; Treatment Outcome; United States | 2021 |
Clinical outcomes of polymer-free, paclitaxel-coated stents vs stent grafts in peripheral arterial disease patients with femoropopliteal artery lesions.
Topics: Aged, 80 and over; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Cardiovascular Agents; Databases, Factual; Drug-Eluting Stents; Endovascular Procedures; Female; Femoral Artery; Graft Occlusion, Vascular; Humans; Japan; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prosthesis Design; Reoperation; Retrospective Studies; Risk Assessment; Risk Factors; Thrombosis; Time Factors; Treatment Outcome; Vascular Patency | 2021 |
Health Care Utilization Following Inpatient Femoropopliteal Revascularization With Drug-Coated Balloon Angioplasty: A Nationwide Cohort Analysis.
Topics: Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Cohort Studies; Femoral Artery; Humans; Inpatients; Paclitaxel; Patient Acceptance of Health Care; Peripheral Arterial Disease; Pharmaceutical Preparations; Popliteal Artery; Prospective Studies; Time Factors; Treatment Outcome; Vascular Patency | 2021 |
Mortality risk after use of a paclitaxel-coated stent in femoropopliteal peripheral artery disease.
Topics: Drug-Eluting Stents; Femoral Artery; Humans; Multicenter Studies as Topic; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Retrospective Studies; Stents; Treatment Outcome; Vascular Patency | 2022 |
Drug-Coated Devices for Peripheral Arterial Disease.
Topics: Angioplasty, Balloon; Atherosclerosis; Coated Materials, Biocompatible; Humans; Paclitaxel; Peripheral Arterial Disease; Stents | 2021 |
An ultralow dose paclitaxel coated drug balloon with an outer protective sheath for peripheral arterial disease treatment.
Topics: Animals; Drug Delivery Systems; Drug Liberation; Paclitaxel; Peripheral Arterial Disease; Safety; Swine | 2021 |
Safety of paclitaxel-coated devices in peripheral artery disease.
Topics: Aged; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Drug-Eluting Stents; Female; Humans; Ischemia; Lower Extremity; Male; Paclitaxel; Patient Safety; Peripheral Arterial Disease; Randomized Controlled Trials as Topic; Treatment Outcome | 2021 |
Outcomes of the paclitaxel-eluting Eluvia stent for long femoropopliteal lesions in Asian patients with predominantly chronic limb-threatening ischemia.
Topics: Chronic Limb-Threatening Ischemia; Drug-Eluting Stents; Femoral Artery; Humans; Limb Salvage; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Retrospective Studies; Treatment Outcome; Vascular Patency | 2021 |
2-Year Outcomes of the Eluvia Drug-Eluting Stent for the Treatment of Complex Femoropopliteal Lesions.
Topics: Drug-Eluting Stents; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Treatment Outcome; Vascular Patency | 2021 |
The Real-World CONSEQUENT ALL COMERS Study: Predictors for Target Lesion Revascularization and Mortality in an Unselected Patient Population.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Cardiovascular Agents; Cause of Death; Coated Materials, Biocompatible; Europe; Female; Femoral Artery; Humans; Malaysia; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Recurrence; Resveratrol; Risk Assessment; Risk Factors; Sex Factors; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2021 |
Efficacy and one-year outcomes of Luminor® paclitaxel-coated drug-eluting balloon in the treatment of popliteal artery atherosclerosis lesions.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Critical Illness; Equipment Design; Female; Humans; Intermittent Claudication; Ischemia; Limb Salvage; Male; Paclitaxel; Peripheral Arterial Disease; Plaque, Atherosclerotic; Popliteal Artery; Prospective Studies; Recurrence; Severity of Illness Index; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2021 |
Positive Initial Experience with the Ranger Paclitaxel-Coated Balloon in BTK Disease.
Topics: Angioplasty, Balloon; Coated Materials, Biocompatible; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Treatment Outcome | 2021 |
Longitudinal Assessment of Safety of Femoropopliteal Endovascular Treatment With Paclitaxel-Coated Devices Among Medicare Beneficiaries: The SAFE-PAD Study.
Topics: Aged; Amputation, Surgical; Antineoplastic Agents, Phytogenic; Drug-Eluting Stents; Endovascular Procedures; Female; Femoral Artery; Humans; Lower Extremity; Male; Medicare; Mortality; Outcome and Process Assessment, Health Care; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; United States | 2021 |
Assessment of 5-Year Mortality Outcomes for Femoropoliteal Interventions Using Drug-Eluting Devices in the REAL-PTX Study.
Topics: Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Pharmaceutical Preparations; Popliteal Artery; Treatment Outcome; Vascular Patency | 2021 |
Should We Use Paclitaxel-Containing Devices for Endovascular Treatment of Peripheral Artery Disease?
Topics: Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery | 2021 |
Directional atherectomy before paclitaxel coated balloon angioplasty in complex femoropopliteal disease: The VIVA REALITY study.
Topics: Angioplasty, Balloon; Atherectomy; Cardiovascular Agents; Coated Materials, Biocompatible; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Time Factors; Treatment Outcome; Vascular Patency | 2021 |
A Patient-Level, Pooled Analysis of Mortality Rates With the Passeo-18 Lux Paclitaxel Drug-Coated Balloon in Peripheral Arterial Disease.
Topics: Angioplasty, Balloon; Chronic Limb-Threatening Ischemia; Coated Materials, Biocompatible; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Pharmaceutical Preparations; Popliteal Artery; Prospective Studies; Time Factors; Treatment Outcome | 2021 |
Paclitaxel-coated peripheral arterial devices are associated with improved overall survival and limb salvage in patients with chronic limb-threatening ischemia.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Angioplasty, Balloon; Cardiovascular Agents; Chronic Disease; Coated Materials, Biocompatible; Equipment Design; Female; Humans; Ischemia; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Progression-Free Survival; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors | 2021 |
A Budget Impact Model for the use of Drug-Eluting Stents in Patients with Symptomatic Lower-Limb Peripheral Arterial Disease: An Australian Perspective.
Topics: Australia; Drug-Eluting Stents; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prosthesis Design; Treatment Outcome; Vascular Patency | 2021 |
Endovascular community response to mortality data in use of paclitaxel devices for peripheral vascular disease.
Topics: Aged; Aged, 80 and over; Cardiovascular Agents; Coated Materials, Biocompatible; Databases, Factual; Drug-Eluting Stents; Endovascular Procedures; Female; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Practice Patterns, Physicians'; Prosthesis Design; Registries; Retrospective Studies; Time Factors; Treatment Outcome | 2021 |
Long-term mortality in patients undergoing lower-limb revascularization with Paclitaxel eluting devices.
Topics: Cardiovascular Agents; Drug-Eluting Stents; Endovascular Procedures; Humans; Lower Extremity; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prosthesis Design; Retrospective Studies; Risk Factors; Treatment Outcome | 2021 |
The impact of percutaneous peripheral interventions on endothelial function.
Topics: Angioplasty, Balloon; Endothelium, Vascular; Female; Femoral Artery; Humans; Male; Paclitaxel; Peripheral Arterial Disease; Treatment Outcome | 2021 |
Overview of the Virtual 2021 FDA's Circulatory System Devices Advisory Panel on Lutonix 014 Drug-Coated Percutaneous Transluminal Angioplasty Catheter for Below-the-Knee Lesions in Critical Limb Ischemia.
Topics: Angioplasty; Angioplasty, Balloon; Cardiovascular System; Chronic Limb-Threatening Ischemia; Coated Materials, Biocompatible; Humans; Ischemia; Limb Salvage; Paclitaxel; Peripheral Arterial Disease; Pharmaceutical Preparations; Popliteal Artery; Prospective Studies; Treatment Outcome; United States; United States Food and Drug Administration; Vascular Access Devices; Vascular Patency | 2021 |
2-Year Results of Paclitaxel-Coated Balloons for Long Femoropopliteal Artery Disease: Evidence From the SFA-Long Study.
Topics: Aged; Amputation, Surgical; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Female; Femoral Artery; Humans; Italy; Kaplan-Meier Estimate; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Proportional Hazards Models; Prospective Studies; Quality of Life; Risk Factors; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2017 |
First-in-man experience of self-expanding nitinol stents combined with drug-coated balloon in the treatment of femoropopliteal occlusive disease.
Topics: Aged; Alloys; Angioplasty, Balloon; Australia; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Endovascular Procedures; Female; Femoral Artery; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Prosthesis Design; Self Expandable Metallic Stents; Severity of Illness Index; Time Factors; Treatment Outcome; Vascular Patency | 2018 |
Impact of Fluoropolymer-Based Paclitaxel Delivery on Neointimal Proliferation and Vascular Healing: A Comparative Peripheral Drug-Eluting Stent Study in the Familial Hypercholesterolemic Swine Model of Femoral Restenosis.
Topics: Angiography; Animals; Cardiovascular Agents; Cell Proliferation; Constriction, Pathologic; Disease Models, Animal; Drug-Eluting Stents; Endovascular Procedures; Femoral Artery; Hyperlipoproteinemia Type II; Methacrylates; Neointima; Paclitaxel; Peripheral Arterial Disease; Polymers; Polyvinyls; Prosthesis Design; Recurrence; Sus scrofa; Time Factors; Tomography, Optical Coherence; Vascular Patency; Wound Healing | 2017 |
Impact of Chronic Renal Failure on Safety and Effectiveness of Paclitaxel-Eluting Stents for Femoropopliteal Artery Disease: Subgroup Analysis from Zilver PTX Post-Market Surveillance Study in Japan.
Topics: Aged; Disease-Free Survival; Drug-Eluting Stents; Female; Femoral Artery; Humans; Japan; Kidney Failure, Chronic; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Tubulin Modulators; Vascular Patency | 2017 |
A universal drug delivery catheter for the treatment of infrapopliteal arterial disease: Results from the multi-center first-in-human study.
Topics: Amputation, Surgical; Angioplasty, Balloon; Cardiovascular Agents; Catheterization, Peripheral; Constriction, Pathologic; Feasibility Studies; Female; Humans; Limb Salvage; Lower Extremity; Male; Paclitaxel; Peripheral Arterial Disease; Prospective Studies; Recurrence; Registries; Risk Factors; Thrombosis; Time Factors; Treatment Outcome; United States; Vascular Access Devices; Vascular Patency | 2018 |
A Pilot Study of Femoropopliteal Artery Revascularisation with a Low Dose Paclitaxel Coated Balloon: Is Predilatation Necessary?
Topics: Aged; Angioplasty, Balloon; Ankle Brachial Index; Cardiovascular Agents; Chi-Square Distribution; Coated Materials, Biocompatible; Constriction, Pathologic; Female; Femoral Artery; Germany; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Pilot Projects; Popliteal Artery; Propensity Score; Proportional Hazards Models; Prospective Studies; Prosthesis Design; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2017 |
Pilot Study to Determine Safety and Efficacy of Paclitaxel Infusion in De Novo Peripheral Lesions Using the Atrium ClearWay Balloon.
Topics: Aged; Angioplasty, Balloon; Cardiovascular Agents; Case-Control Studies; Humans; Lower Extremity; Paclitaxel; Peripheral Arterial Disease; Pilot Projects; Prospective Studies | 2017 |
Calcified plaque modification alters local drug delivery in the treatment of peripheral atherosclerosis.
Topics: Antineoplastic Agents, Phytogenic; Atherosclerosis; Biological Transport; Calcinosis; Humans; Lower Extremity; Paclitaxel; Peripheral Arterial Disease; Plaque, Atherosclerotic | 2017 |
Revascularization of the superficial femoral artery with paclitaxel-coated balloon for claudication.
Topics: Aged; Angiography; Angioplasty, Balloon; Cohort Studies; Drug-Eluting Stents; Female; Femoral Artery; Follow-Up Studies; Humans; Intermittent Claudication; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Prospective Studies; Risk Assessment; Treatment Outcome; Vascular Patency | 2018 |
Long-Term Results from the MAJESTIC Trial of the Eluvia Paclitaxel-Eluting Stent for Femoropopliteal Treatment: 3-Year Follow-up.
Topics: Aged; Antineoplastic Agents, Phytogenic; Disease-Free Survival; Drug-Eluting Stents; Female; Femoral Artery; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Treatment Outcome; Ultrasonography, Doppler, Duplex; Vascular Patency | 2017 |
Drug-Coated Balloon Treatment for Femoropopliteal Artery Disease: The IN.PACT Global Study De Novo In-Stent Restenosis Imaging Cohort.
Topics: Aged; Amputation, Surgical; Angiography; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Endovascular Procedures; Female; Femoral Artery; Humans; Kaplan-Meier Estimate; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Recurrence; Stents; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Duplex; Vascular Access Devices; Vascular Patency | 2017 |
Short-Term Results of Eluvia Paclitaxel-Eluting Stent in External Iliac and Femoropopliteal Lesions.
Topics: Adult; Aged; Aged, 80 and over; Drug-Eluting Stents; Female; Femoral Artery; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Retrospective Studies; Treatment Outcome | 2017 |
Long-Term Effectiveness of the Zilver PTX Drug-Eluting Stent for Femoropopliteal Peripheral Artery Disease in Patients with No Patent Tibial Runoff Vessels-Results from the Zilver PTX Japan Post-Market Surveillance Study.
Topics: Aged; Amputation, Surgical; Drug-Eluting Stents; Female; Femoral Artery; Humans; Ischemia; Japan; Lower Extremity; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Product Surveillance, Postmarketing; Retrospective Studies; Tibia; Tubulin Modulators; Vascular Patency | 2018 |
Full Drug-Eluting Stent Jacket: Two-Year Results of a Single-Center Experience With Zilver PTX Stenting for Long Lesions in the Femoropopliteal Arteries.
Topics: Aged; Alloys; Angioplasty, Balloon; Cardiovascular Agents; Drug-Eluting Stents; Female; Femoral Artery; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prosthesis Design; Recurrence; Retrospective Studies; Risk Factors; Self Expandable Metallic Stents; Time Factors; Treatment Outcome; Vascular Patency | 2018 |
Drug-Coated Balloon Treatment of Femoropopliteal Lesions for Patients With Intermittent Claudication and Ischemic Rest Pain: 2-Year Results From the IN.PACT Global Study.
Topics: Aged; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Female; Femoral Artery; Humans; Intermittent Claudication; Ischemia; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Recurrence; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2018 |
1-Year All-Comers Analysis of the Eluvia Drug-Eluting Stent for Long Femoropopliteal Lesions After Suboptimal Angioplasty.
Topics: Aged; Angioplasty; Cardiovascular Agents; Chronic Disease; Constriction, Pathologic; Drug-Eluting Stents; Female; Femoral Artery; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prosthesis Design; Recurrence; Retrospective Studies; Time Factors; Treatment Outcome; Vascular Calcification; Vascular Patency | 2018 |
Zilver PTX Post-market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 2-Year Results.
Topics: Aged; Drug-Eluting Stents; Female; Femoral Artery; Humans; Japan; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Time Factors; Treatment Outcome; Tubulin Modulators; Ultrasonography, Doppler, Duplex; Vascular Patency | 2019 |
Drug-Coated Balloon Treatment of Femoropopliteal Lesions for Patients With Intermittent Claudication and Ischemic Rest Pain.
Topics: Aged; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Equipment Design; Female; Femoral Artery; Humans; Intermittent Claudication; Ischemia; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Risk Factors; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2019 |
Assessing the Long-term Safety of Endovascular Therapies-The Case of Peripheral Paclitaxel-Coated Devices.
Topics: Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease | 2019 |
One-Year Clinical Outcomes of the Legflow Drug-Coated Balloon for the Treatment of Femoropopliteal Occlusions Registry.
Topics: Aged; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Critical Illness; Equipment Design; Europe; Female; Femoral Artery; Humans; Intermittent Claudication; Ischemia; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Recurrence; Registries; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2019 |
An Experimental Study of Paclitaxel Embolisation During Drug Coated Balloon Angioplasty.
Topics: Angioplasty, Balloon; Animals; Chemoembolization, Therapeutic; Coated Materials, Biocompatible; Disease Models, Animal; Femoral Artery; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Rabbits; Renal Artery; Treatment Outcome | 2019 |
Comparison between paclitaxel-coated balloon and standard uncoated balloon in the treatment of femoropopliteal long lesions in diabetics.
Topics: Aged; Angiography; Angioplasty; Angioplasty, Balloon; Antineoplastic Agents, Phytogenic; Arterial Occlusive Diseases; Atherosclerosis; Coated Materials, Biocompatible; Diabetes Complications; Diabetes Mellitus; Female; Femoral Artery; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Treatment Outcome | 2019 |
Outcomes After Drug-Coated Balloon Treatment of Femoropopliteal Lesions in Patients With Critical Limb Ischemia: A Post Hoc Analysis From the IN.PACT Global Study.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Angioplasty, Balloon; Cardiovascular Agents; Clinical Trials as Topic; Coated Materials, Biocompatible; Critical Illness; Equipment Design; Female; Femoral Artery; Humans; Intermittent Claudication; Ischemia; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Progression-Free Survival; Risk Factors; Time Factors; Vascular Access Devices; Vascular Patency | 2019 |
Paclitaxel Drug-Coated Balloons in Peripheral Artery Disease: Who's Trying to Shoot the Football Star?
Topics: Angioplasty, Balloon; Football; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery | 2019 |
Intrinsic coating morphology modulates acute drug transfer in drug-coated balloon therapy.
Topics: Angioplasty, Balloon; Cell Death; Cell Survival; Cells, Cultured; Coated Materials, Biocompatible; Endothelial Cells; Flow Cytometry; Humans; Microscopy, Electron, Scanning; Models, Theoretical; Paclitaxel; Peripheral Arterial Disease; Resins, Plant; Urea | 2019 |
Comments on the current crisis with paclitaxel eluting lower extremity endovascular devices.
Topics: Angioplasty, Balloon; Device Approval; Drug-Eluting Stents; Follow-Up Studies; Humans; Meta-Analysis as Topic; Paclitaxel; Peripheral Arterial Disease; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration | 2019 |
Paclitaxel-Coated Balloons and Eluting Stents: Is There a Mortality Risk in Patients With Peripheral Artery Disease?
Topics: Antineoplastic Agents, Phytogenic; Consensus; Drug-Eluting Stents; Humans; Meta-Analysis as Topic; Neoplasms; Paclitaxel; Peripheral Arterial Disease; Proportional Hazards Models; Survival Analysis | 2019 |
Vascular response to paclitaxel-eluting nitinol self-expanding stent in superficial femoral artery lesions: post-implantation angioscopic findings from the SHIMEJI trial (Suppression of vascular wall Healing after IMplantation of drug Eluting peripheral s
Topics: Aged; Aged, 80 and over; Alloys; Angioscopy; Cardiovascular Agents; Cell Proliferation; Drug-Eluting Stents; Endovascular Procedures; Female; Femoral Artery; Humans; Japan; Male; Middle Aged; Neointima; Paclitaxel; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Predictive Value of Tests; Prospective Studies; Prosthesis Design; Registries; Risk Factors; Self Expandable Metallic Stents; Time Factors; Treatment Outcome; Wound Healing | 2019 |
Amputation-free Survival in Patients with Critical Limb Ischemia Treated with Paclitaxel-eluting Stents and Paclitaxel-coated Balloons.
Topics: Aged; Amputation, Surgical; Angioplasty, Balloon; Cardiovascular Agents; Clinical Decision-Making; Coated Materials, Biocompatible; Critical Illness; Drug-Eluting Stents; Female; Humans; Ischemia; Limb Salvage; Male; Middle Aged; Paclitaxel; Patient Selection; Peripheral Arterial Disease; Progression-Free Survival; Prosthesis Design; Retrospective Studies; Risk Factors; Time Factors; Vascular Access Devices; Vascular Patency | 2020 |
One-Year Late Lumen Loss between A Polymer-Coated Paclitaxel-Eluting Stent (Eluvia) and a Polymer-Free Paclitaxel-Coated Stent (Zilver PTX) for Femoropopliteal Disease.
Topics: Angiography; Antineoplastic Agents, Phytogenic; Drug-Eluting Stents; Endovascular Procedures; Female; Femoral Artery; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Paclitaxel; Peripheral Arterial Disease; Polymers; Popliteal Artery; Ultrasonography, Doppler, Duplex | 2020 |
Vessel Calcification as a Risk Factor for In-Stent Restenosis in Complex Femoropopliteal Lesions After Zilver PTX Paclitaxel-Coated Stent Placement.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Cardiovascular Agents; Cilostazol; Constriction, Pathologic; Drug-Eluting Stents; Endovascular Procedures; Female; Femoral Artery; Humans; Japan; Limb Salvage; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Progression-Free Survival; Prosthesis Design; Recurrence; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Vascular Calcification; Vascular Patency | 2019 |
Paclitaxel-coated balloons and stents for the treatment of peripheral artery disease: proceedings from the Cardiovascular Research Technologies (CRT) 2019 Town Hall.
Topics: Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Femoral Artery; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Stents; Treatment Outcome | 2019 |
2-year results of paclitaxel-eluting balloons for femoropopliteal artery disease: evidence from a multicenter registry.
Topics: Aged; Angioplasty, Balloon; Ankle Brachial Index; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Exercise Test; Female; Femoral Artery; Humans; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Quality of Life; Recurrence; Registries; Stents; Surveys and Questionnaires; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2013 |
Percutaneous revascularization for peripheral arterial disease: paclitaxel saves the day.
Topics: Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Drug-Eluting Stents; Female; Femoral Artery; Humans; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Vascular Access Devices | 2013 |
How should I treat a restenosis after superficial femoral artery stenting?
Topics: Aged; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Equipment Design; Femoral Artery; Humans; Male; Paclitaxel; Peripheral Arterial Disease; Predictive Value of Tests; Recurrence; Stents; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography, Doppler; Vascular Access Devices | 2013 |
Monitoring of gadolinium-BOPTA uptake into the vessel wall during magnetic resonance (MR)-guided angioplasty of the peripheral arteries with a paclitaxel/gadolinium-BOPTA-coated balloon: an experimental study at 3 Tesla.
Topics: Angioplasty, Balloon; Animals; Arterial Occlusive Diseases; Contrast Media; Drug Monitoring; Drug-Eluting Stents; Iliac Artery; Magnetic Resonance Angiography; Meglumine; Organometallic Compounds; Paclitaxel; Peripheral Arterial Disease; Surgery, Computer-Assisted; Swine | 2014 |
Commentary: how do we deal with dissection after angioplasty?
Topics: Angioplasty, Balloon; Aortic Dissection; Cardiovascular Agents; Coated Materials, Biocompatible; Female; Femoral Artery; Humans; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Vascular Access Devices | 2013 |
Cost-effectiveness analysis of paclitaxel-coated balloons for endovascular therapy of femoropopliteal arterial obstructions.
Topics: Angioplasty, Balloon; Budgets; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Cost Savings; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Equipment Design; Femoral Artery; Health Care Costs; Health Expenditures; Hospital Costs; Humans; Insurance, Health, Reimbursement; Length of Stay; Models, Economic; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; Vascular Access Devices | 2013 |
Commentary: aligning incentives of payer, facility, and provider: the lynchpin of providing more cost-effective care.
Topics: Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Femoral Artery; Health Care Costs; Humans; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Vascular Access Devices | 2013 |
Paclitaxel-eluting balloon vs. standard angioplasty to reduce recurrent restenosis in diabetic patients with in-stent restenosis of the superficial femoral and proximal popliteal arteries: the DEBATE-ISR study.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Diabetic Angiopathies; Equipment Design; Female; Femoral Artery; Humans; Italy; Kaplan-Meier Estimate; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Radiography; Retreatment; Risk Factors; Secondary Prevention; Time Factors; Treatment Outcome; Ultrasonography; Vascular Access Devices | 2014 |
Commentary: treatment of femoropopliteal in-stent restenosis for patients with diabetes: do we have an answer to the DEBATE?
Topics: Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Diabetic Angiopathies; Female; Femoral Artery; Humans; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Vascular Access Devices | 2014 |
Percutaneous transluminal angioplasty with drug-eluting balloons for salvage of infrainguinal bypass grafts.
Topics: Aged; Aged, 80 and over; Angiography, Digital Subtraction; Angioplasty, Balloon; Blood Vessel Prosthesis Implantation; Cardiovascular Agents; Coated Materials, Biocompatible; Feasibility Studies; Female; Graft Occlusion, Vascular; Humans; Lower Extremity; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Prospective Studies; Salvage Therapy; Saphenous Vein; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2014 |
Commentary: is the drug-eluting balloon the answer to the epidemic of restenosis?
Topics: Angioplasty, Balloon; Blood Vessel Prosthesis Implantation; Cardiovascular Agents; Coated Materials, Biocompatible; Female; Graft Occlusion, Vascular; Humans; Lower Extremity; Male; Paclitaxel; Peripheral Arterial Disease; Salvage Therapy; Saphenous Vein; Vascular Access Devices | 2014 |
Drug-eluting balloons for the treatment of the superficial femoral artery in-stent restenosis: 2-year follow-up.
Topics: Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Equipment Design; Femoral Artery; Follow-Up Studies; Humans; Italy; Paclitaxel; Peripheral Arterial Disease; Prospective Studies; Recurrence; Registries; Retreatment; Stents; Time Factors; Treatment Outcome; Vascular Access Devices | 2014 |
Paclitaxel-coated balloons for failing peripheral bypass grafts: the BYPACS study.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Angiography, Digital Subtraction; Angioplasty, Balloon; Blood Flow Velocity; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Cardiovascular Agents; Constriction, Pathologic; Drug Carriers; Equipment Design; Female; Graft Occlusion, Vascular; Humans; Kaplan-Meier Estimate; Limb Salvage; London; Male; Middle Aged; Multivariate Analysis; Paclitaxel; Peripheral Arterial Disease; Proportional Hazards Models; Prospective Studies; Prosthesis Failure; Regional Blood Flow; Reoperation; Risk Factors; Time Factors; Treatment Failure; Ultrasonography, Doppler, Duplex; Vascular Access Devices; Veins | 2014 |
Effectiveness of Zilver PTX eluting stent in TASC C/D lesions and restenosis.
Topics: Aged; Aged, 80 and over; Alloys; Cardiovascular Agents; Constriction, Pathologic; Disease-Free Survival; Drug-Eluting Stents; Endovascular Procedures; Female; Humans; Kaplan-Meier Estimate; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Prosthesis Design; Recurrence; Time Factors; Treatment Outcome; Ultrasonography, Doppler; Vascular Patency | 2014 |
Extensive arterial repair one year after paclitaxel-coated nitinol drug-eluting stent vs. bare-metal stent implantation in the superficial femoral artery.
Topics: Aged; Aged, 80 and over; Alloys; Angiography; Angioscopy; Drug-Eluting Stents; Female; Femoral Artery; Follow-Up Studies; Humans; Male; Metals; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Stents | 2015 |
David versus Goliath: the first round.
Topics: Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Drug-Eluting Stents; Female; Humans; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Vascular Access Devices | 2014 |
Drug-eluting balloons for femoropopliteal lesions show better performance in de novo stenosis or occlusion than in restenosis.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Critical Illness; Equipment Design; Female; Femoral Artery; Humans; Intermittent Claudication; Ischemia; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Recurrence; Stents; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2015 |
Biological effect of orbital atherectomy and adjunctive paclitaxel-coated balloon therapy on vascular healing and drug retention: early experimental insights into the familial hypercholesterolaemic swine model of femoral artery stenosis.
Topics: Angioplasty, Balloon; Animals; Antineoplastic Agents, Phytogenic; Atherectomy; Combined Modality Therapy; Constriction, Pathologic; Disease Models, Animal; Femoral Artery; Hyperlipoproteinemia Type II; Paclitaxel; Peripheral Arterial Disease; Swine; Tomography, Optical Coherence; Ultrasonography, Interventional; Wound Healing | 2014 |
Outcomes of Zilver PTX stent implantation for the treatment of complex femoropopliteal artery disease.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Angioplasty, Balloon; Cardiovascular Agents; Constriction, Pathologic; Disease-Free Survival; Drug-Eluting Stents; Femoral Artery; Humans; Japan; Kaplan-Meier Estimate; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prosthesis Design; Recurrence; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Duplex; Vascular Patency | 2016 |
The THUNDER trial results: clearing the way or ushering the storm?
Topics: Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Female; Femoral Artery; Humans; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Vascular Access Devices | 2015 |
Vascular response after Zilver PTX stent implantation for superficial femoral artery lesions: serial optical coherence tomography findings at 6 and 12 months.
Topics: Aged; Aged, 80 and over; Alloys; Cardiovascular Agents; Drug-Eluting Stents; Female; Femoral Artery; Follow-Up Studies; Humans; Male; Neointima; Paclitaxel; Peripheral Arterial Disease; Predictive Value of Tests; Retrospective Studies; Risk Factors; Sensitivity and Specificity; Tomography, Optical Coherence; Treatment Outcome | 2015 |
Comparison of SFA lesion treatment with Zilver PTX in diabetics vs. non-diabetics: 2-year clinical and functional results.
Topics: Aged; Aged, 80 and over; Alloys; Amputation, Surgical; Cardiovascular Agents; Diabetic Angiopathies; Drug-Eluting Stents; Endovascular Procedures; Female; Femoral Artery; Humans; Italy; Kaplan-Meier Estimate; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Prosthesis Design; Retreatment; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Vascular Patency | 2017 |
Intravascular ultrasound measurements after drug-eluting stent placement in femoropopliteal lesions: determining predictors of restenosis.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Area Under Curve; Blood Flow Velocity; Cardiovascular Agents; Constriction, Pathologic; Critical Illness; Drug-Eluting Stents; Female; Femoral Artery; Humans; Ischemia; Japan; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Predictive Value of Tests; Prosthesis Design; Radiography; Recurrence; Regional Blood Flow; Retrospective Studies; Risk Factors; ROC Curve; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Duplex; Ultrasonography, Interventional | 2015 |
Commentary: intravascular ultrasound for femoropopliteal stenting: can it predict outcomes with current-generation stents?
Topics: Angioplasty, Balloon; Cardiovascular Agents; Drug-Eluting Stents; Female; Femoral Artery; Humans; Ischemia; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Ultrasonography, Interventional | 2015 |
Two-pronged approach holds promise against peripheral arterial disease.
Topics: Angioplasty, Balloon; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Humans; Paclitaxel; Peripheral Arterial Disease | 2015 |
Drug-Eluting vs Standard Balloon Angioplasty for Iliac Stent Restenosis: Midterm Results.
Topics: Aged; Angioplasty, Balloon; Ankle Brachial Index; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Female; Humans; Iliac Artery; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Radiography; Recurrence; Retreatment; Retrospective Studies; Risk Factors; Stents; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Color; Vascular Access Devices; Vascular Patency | 2015 |
Angioplasty with paclitaxel coated balloon reduces restenosis in peripheral artery disease.
Topics: Angioplasty, Balloon; Female; Femoral Artery; Humans; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery | 2015 |
1-Year Results of the ZEPHYR Registry (Zilver PTX for the Femoral Artery and Proximal Popliteal Artery): Predictors of Restenosis.
Topics: Aged; Aged, 80 and over; Cardiovascular Agents; Drug-Eluting Stents; Endovascular Procedures; Female; Femoral Artery; Humans; Japan; Kaplan-Meier Estimate; Linear Models; Male; Multivariate Analysis; Odds Ratio; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Proportional Hazards Models; Prospective Studies; Prosthesis Design; Radiography; Recurrence; Risk Factors; Thrombosis; Time Factors; Treatment Outcome; Ultrasonography, Interventional; Vascular Patency | 2015 |
Impact of Paclitaxel Dose on Tissue Pharmacokinetics and Vascular Healing: A Comparative Drug-Coated Balloon Study in the Familial Hypercholesterolemic Swine Model of Superficial Femoral In-Stent Restenosis.
Topics: Animals; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Disease Models, Animal; Endovascular Procedures; Femoral Artery; Fibrin; Hyperlipoproteinemia Type II; Metals; Neointima; Paclitaxel; Peripheral Arterial Disease; Radiography; Stents; Swine; Tissue Distribution; Vascular Access Devices; Wound Healing | 2015 |
Drug-coated balloons--the importance of packing and dosing antiproliferative drugs.
Topics: Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Female; Femoral Artery; Humans; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Vascular Access Devices | 2015 |
Dextran sulfate as a drug delivery platform for drug-coated balloons: Preparation, characterization, in vitro drug elution, and smooth muscle cell response.
Topics: Angioplasty, Balloon; Cells, Cultured; Coated Materials, Biocompatible; Dextran Sulfate; Drug Delivery Systems; Humans; Materials Testing; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Paclitaxel; Peripheral Arterial Disease | 2016 |
Treatment of TASC C and D Femoropoliteal Lesions with Paclitaxel eluting Stents: 12 month Results of the STELLA-PTX Registry.
Topics: Aged; Combined Modality Therapy; Drug-Eluting Stents; Female; Femoral Artery; Humans; Intermittent Claudication; Ischemia; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Registries; Time Factors | 2015 |
Paclitaxel-coated versus plain balloon angioplasty in the treatment of infrainguinal vein bypass stenosis.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Angioplasty, Balloon; Austria; Cardiovascular Agents; Coated Materials, Biocompatible; Equipment Design; Female; Graft Occlusion, Vascular; Humans; Kaplan-Meier Estimate; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Proportional Hazards Models; Reoperation; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency; Veins | 2016 |
Missing the Forest for the Trees?: Drug-Eluting Balloon Treatment for Infrapopliteal Disease.
Topics: Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Female; Humans; Intermittent Claudication; Ischemia; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Vascular Access Devices | 2015 |
A Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease.
Topics: Angioplasty, Balloon; Female; Femoral Artery; Humans; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery | 2015 |
A Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease.
Topics: Angioplasty, Balloon; Female; Femoral Artery; Humans; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery | 2015 |
A Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease.
Topics: Angioplasty, Balloon; Female; Femoral Artery; Humans; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery | 2015 |
Paclitaxel-Eluting Balloon vs Standard Angioplasty to Reduce Restenosis in Diabetic Patients With In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Arteries: Three-Year Results of the DEBATE-ISR Study.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Cardiovascular Agents; Chi-Square Distribution; Constriction, Pathologic; Critical Illness; Diabetic Angiopathies; Drug-Eluting Stents; Female; Femoral Artery; Historically Controlled Study; Humans; Ischemia; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Prosthesis Design; Recurrence; Registries; Retreatment; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Vascular Patency | 2016 |
Evaluation of the Biodegradable Igaki-Tamai Scaffold After Drug-Eluting Balloon Treatment of De Novo Superficial Femoral Artery Lesions: The GAIA-DEB Study.
Topics: Absorbable Implants; Aged; Angioplasty, Balloon; Ankle Brachial Index; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Female; Femoral Artery; Germany; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Pilot Projects; Prospective Studies; Recurrence; Retreatment; Surveys and Questionnaires; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Duplex; Vascular Access Devices; Vascular Patency | 2016 |
Early Post-Registry Experience With Drug-Eluting Stents in the Superficial Femoral Artery.
Topics: Aged; Amputation, Surgical; Cardiovascular Agents; Drug-Eluting Stents; Endovascular Procedures; Female; Femoral Artery; Humans; Intermittent Claudication; Ischemia; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Prosthesis Design; Recurrence; Registries; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Vascular Patency | 2016 |
Intravascular Ultrasound-Derived Stent Dimensions as Predictors of Angiographic Restenosis Following Nitinol Stent Implantation in the Superficial Femoral Artery.
Topics: Aged; Aged, 80 and over; Alloys; Angiography; Angioplasty, Balloon; Area Under Curve; Cardiovascular Agents; Chi-Square Distribution; Constriction, Pathologic; Drug-Eluting Stents; Female; Femoral Artery; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Paclitaxel; Peripheral Arterial Disease; Predictive Value of Tests; Prosthesis Design; Recurrence; Retrospective Studies; Risk Factors; ROC Curve; Stents; Time Factors; Treatment Outcome; Ultrasonography, Interventional; Vascular Patency | 2016 |
Single-Center Experience With Lutonix Drug-Coated Balloons in Infrapopliteal Arteries.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Female; Germany; Humans; Intermittent Claudication; Ischemia; Kaplan-Meier Estimate; Limb Salvage; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Recurrence; Retrospective Studies; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2016 |
1-Year Results of Paclitaxel-Coated Balloons for Long Femoropopliteal Artery Disease: Evidence From the SFA-Long Study.
Topics: Aged; Angioplasty, Balloon; Ankle Brachial Index; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Equipment Design; Female; Femoral Artery; Humans; Italy; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Quality of Life; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Calcification; Vascular Patency | 2016 |
A single center experience of Zilver PTX for femoro-popliteal lesions.
Topics: Aged; Angiography; Angioplasty, Balloon; Cardiovascular Agents; Constriction, Pathologic; District of Columbia; Drug-Eluting Stents; Female; Femoral Artery; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prosthesis Design; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Ultrasonography, Doppler; Vascular Patency | 2016 |
[Drug coated balloon with paclitaxel for the treatment of symptomatic peripheral artery disease: early and midterm results].
Topics: Aged; Amputation, Surgical; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Female; Femoral Artery; Humans; Kaplan-Meier Estimate; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Retrospective Studies; Time Factors; Treatment Outcome | 2016 |
Incidence and its characteristics of repetition of reintervention after drug-eluting stent implantation for femoropopliteal lesion.
Topics: Aged; Aged, 80 and over; Angiography; Cardiovascular Agents; Critical Illness; Databases, Factual; Disease-Free Survival; Drug-Eluting Stents; Endovascular Procedures; Female; Femoral Artery; Humans; Incidence; Ischemia; Japan; Kaplan-Meier Estimate; Male; Multivariate Analysis; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Proportional Hazards Models; Prosthesis Design; Recurrence; Retreatment; Risk Factors; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2016 |
Ultrasound Plus Paclitaxel Trumps Drug-Coated Balloon: Progress in the Periphery?
Topics: Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Femoral Artery; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Treatment Outcome | 2016 |
Directional Atherectomy With Antirestenotic Therapy vs Drug-Coated Balloon Angioplasty Alone for Isolated Popliteal Artery Lesions.
Topics: Aged; Aged, 80 and over; Aneurysm; Angiography; Angioplasty, Balloon; Anticoagulants; Atherectomy; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Equipment Design; Female; Germany; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Popliteal Artery; Risk Factors; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2017 |
Acute hypersensitivity reaction to femoral drug-coated balloons.
Topics: Acute Disease; Aged; Amputation, Surgical; Anaphylaxis; Angiography; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Drug Hypersensitivity; Femoral Artery; Humans; Male; Paclitaxel; Peripheral Arterial Disease; Treatment Outcome; Vascular Access Devices | 2017 |
Comparison of Drug-Eluting Balloon and Standard Balloon Angioplasty for Infrapopliteal Arterial Diseases in Diabetic Patients.
Topics: Aged; Angioplasty, Balloon; Cardiovascular Agents; Chi-Square Distribution; Coated Materials, Biocompatible; Diabetic Angiopathies; Equipment Design; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Recurrence; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Turkey; Vascular Access Devices; Vascular Patency | 2016 |
Bare Metal Versus Paclitaxel-Eluting Stents for Long Femoropopliteal Lesions: Prospective Cohorts Comparison Using a Propensity Score-Matched Analysis.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Cardiovascular Agents; Chi-Square Distribution; Disease-Free Survival; Drug-Eluting Stents; Female; Femoral Artery; France; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Logistic Models; Male; Matched-Pair Analysis; Metals; Middle Aged; Multivariate Analysis; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Propensity Score; Proportional Hazards Models; Prospective Studies; Prosthesis Design; Registries; Risk Factors; Stents; Time Factors; Treatment Outcome; Vascular Patency | 2017 |